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ABSTRACT 
The Swedish HIV-1 epidemic is characterized by a wide variation in subtypes due to 
migration and travel. The aims of this thesis were to investigate molecular methods for 
estimating time to diagnosis and epidemiological tools for estimating the proportion of 
undiagnosed individuals with HIV-1 in Sweden, as well as to update the knowledge on 
transmitted and pre-treatment drug resistance (TDR and PDR) among persons living with 
HIV-1 in Sweden.  
In Paper I we found that viral diversity estimated by the proportion of mixed base calls in pol 
gene sequences is an indicator of whether a HIV-1 infection is recent (≤1 year) or chronic. A 
cutoff of 0.47% mixed base calls identified recent infections with a sensitivity of 89% and a 
specificity of 75%.  
In Paper II we studied TDR in newly diagnosed individuals (n=1,713, 71% coverage) in 
2010-2016 in Sweden. The prevalence of TDR was 7.1% (95% CI 5.8-8.3%) and resistance 
to non-nucleoside reverse transcriptase inhibitors (NNRTI) increased significantly from 1.5% 
in 2010 to 6.2% in 2016 and was related to infection/origin in sub-Saharan Africa. A 
transmission cluster in men having sex with men with the M41L mutation was traced back to 
the 1990´s.  
In Paper III we evaluated two mathematical models for estimation of the proportion of 
undiagnosed individuals with HIV-1 in Sweden, SSOPHIE and the ECDC Modelling tool. 
The model estimates for 2013 were 26% (n=2,100; 90% plausibility range 900-5,000) and 
21% (n=2,013; 95% CI 1,831-2,189), respectively. The wide confidence bounds and 
problems to account for migration limited the value of the results. We concluded that 
improvements of models and better data on migration are needed. 
In Paper IV we investigated PDR in individuals diagnosed in Sweden 2017-2019 (n=224) 
using an in-house high-throughput sequencing (HTS) assay with a detection limit of 1% for 
minority viral variants. HTS was successful in 87% of samples and failure was associated 
with low viral loads. Drug resistance mutations (DRMs) in protease/reverse transcriptase 
were detected in 49% of patients and in 18% of patients the DRMs were at levels ≥20% of 
the viral population. DRMs above 20% were mainly towards NNRTIs and correlated with 
previous ART exposure (p=0.001) and origin in Asia (p=0.007). Integrase strand transfer 
inhibitor (INSTI) DRM were rare and only found in levels <20% of the total viral population. 
In conclusion, we have confirmed that viral diversity is a useful biomarker of time to 
diagnosis in HIV-infection and have identified important complications with estimating the 
proportion of undiagnosed HIV-1 infections in settings with high levels of migration. We 
have shown that the global increase in NNRTI-resistance is mirrored among HIV-positive 
migrants in Sweden and we have contributed to the knowledge about the utility of HTS in 
drug resistance testing of HIV-1.  
POPULÄRVETENSKAPLIG SAMMANFATTNING 
Syftet med min avhandling är att utveckla och studera metoder för att bättre kunna avgöra hur 
länge en individ varit smittad med humant immunbristvirus typ 1 (HIV-1) och hur många 
individer med odiagnosticerad HIV-1 infektion som vistas i Sverige. Detta sker genom 
undersökning av virusets arvsmassa och utvärdering av matematiska modeller. Vi ville också 
undersöka hur vanligt det är med överförd läkemedelsresistens och resistens innan 
behandling i Sverige. För att studera resistens i detalj har vi använt nya avancerade metoder 
för djupsekvensering som möjliggör fynd av även små mängder resistent virus. 
 HIV-1 har givit upphov till en världsomspännande epidemi och idag lever uppskattningsvis 
37,9 miljoner människor med infektionen varav de flesta i Afrika. Viruset angriper 
immunförsvarets T-hjälparceller och utan behandling utvecklas i de flesta fall AIDS 
(förvärvat immunbristsyndrom) inom ett decennium. Eftersom HIV-1 under lång tid inte ger 
tydliga symtom kan en infektion förbli oupptäckt länge. Idag finns effektiv behandling med 
kombinationer av läkemedel som angriper virusets förmåga att föröka sig i kroppen, vilket 
kan eliminera smittsamhet och ger möjlighet till ett långt och friskt liv. Viruset har dock en 
inneboende förmåga att snabbt förändra sig (mutera) och om resistens mot läkemedel uppstår 
kan behandlingen bli ineffektiv.  
Under 1980-talets första hälft var det framförallt män som har sex med män (MSM) och 
individer med intravenöst missbruk som infekterades med HIV-1 i Sverige. Migration och 
resor har förändrat bilden och andelen HIV-1 diagnoser hos individer födda i ett annat land 
och personer som blivit infekterade heterosexuellt har ökat kraftigt. Det senaste decenniet har 
cirka 450 individer per år diagnosticerats med HIV-1 och knappt 8000 individer lever idag 
med känd HIV-1 i Sverige. Tre fjärdedelar av nya HIV-1 diagnoser 2018 ställdes hos 
individer födda i ett annat land och andelen HIV-1 diagnoser hos MSM med utländskt 
ursprung ökar. I Sverige finns nu en stor variation av genetiska varianter (subtyper) av HIV-
1, vilket speglar den svenska HIV-1 epidemins globala kopplingar. 
De viktigaste slutsatserna från avhandlingen är: 
▪ Information om virusets arvsmassa från rutintestning för resistens ger ledtrådar till hur 
länge en individ varit smittad. 
▪ Uppskattningen av antalet odiagnosticerade individer med HIV-1 i Sverige är osäker 
och det behövs både utveckling av analytiska metoder och säkrare data om migration. 
▪ Resistens mot NNRTI-läkemedel är hög hos HIV-positiva från Afrika söder om 
Sahara men finns även hos andra grupper vid HIV-diagnos i Sverige. Tidigare HIV-
behandling och ursprung i Asien ökar risken för att bära på resistent virus vid HIV-
diagnos i Sverige. 
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1 INTRODUCTION 
Thirty-six years after the discovery of HIV-1 in 1983 and over 20 years after the introduction 
of efficient antiretroviral therapy (ART), the virus is still a global health challenge. 
Undiagnosed infections, lack of an efficient vaccine, and emerging antiretroviral resistance 
(HIVDR) are major obstacles to provide effective treatment for everyone in need and to stop 
the transmission of HIV-1 worldwide. 
An estimated 37.9 million people were living with HIV-1 and 23.3 million were on ART at 
the end of 2018. The most affected region is eastern and southern Africa with 20.6 million 
people living with HIV-1, whereof 13.8 million on treatment. [1] However, the virus is 
spreading rapidly also in countries like Russia and China. [2] Modern ART has transformed 
HIV-1 from a deadly infection into a treatable chronic condition with limited or even 
eliminated risk of transmission [3-5], but still no cure or protective vaccine is available. In 
2018, 770,000 people died from HIV-1 infection, a decline with 33% since 2010. [1] 
Sweden is a low prevalence and low incidence country for HIV-1 but mirrors the world in 
that migrant populations from high endemic countries are well-represented in the Swedish 
national HIV-1 positive population. By studying HIV-1 in Sweden, we thereby contribute to 
knowledge of HIV-1 both nationally and globally.  
1.1 HIV-1 VIROLOGY 
1.1.1 The virus and its origin 
HIV-1 belongs to the genus lentiviridae within the retroviridae family. The single-stranded 
positive sense RNA-genome has a length of approximately 10,000 base pairs (bp) and 
contains nine genes in three reading frames. The three major genes are: gag, that encodes the 
major structural proteins (matrix protein p17 and capsid protein p24), pol that encodes the 
enzymes reverse transcriptase (RT), integrase (IN) and protease (PR), and env that encodes 
envelope glycoproteins (gp41 and gp120). The genome also contains six genes that encode 
proteins with regulatory function; tat, rev, vif, vpr, vpu and nef. Both 3´and 5´ends of the 
RNA genome contain LTRs (long terminal repeats) that are important for proviral insertion in 
the host genome after reverse transcription as well as for replication, transcription and 
translation. [6] 
 
Fig 1. The HIV-1 genome. Wikimedia Commons. Thomas Splettstoesser (www.scistyle.com) 
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The viral particle contains two copies of the genome within a conical nucleocapsid. The 
nucleocapsid is surrounded by a host cell derived envelope with viral proteins gp120 and 
gp41. The virion also contains the viral enzymes RT, PR and IN [7] 
 
Fig 2. The HIV-1 virion. Wikimedia Commons. Thomas Splettstoesser (www.scistyle.com) 
HIV-1 originates from the simian virus SIV that is found in chimpanzees and gorillas in 
Cameroon. Multiple cross-species introductions of SIV in humans have resulted in four 
known groups related to different zoonotic events (M, N, O and P). [8] HIV-1 group M (M 
for “major”) is the pandemic branch of HIV-1 that represents most infections in the world and 
is estimated to originate from transmission of SIV to man in Central Africa in the early 
1900s. [9, 10] The pandemic spread of group M within Africa is not only related to the virus 
itself, but to sociodemographic factors during the early 20th century such as migration [11, 
12], unclean practises in medicine [13], increased prevalence of genital ulcer disease [14] and 
exploitation of the region by European colonizers establishing transportation networks and 
inferring social changes. [12] From the local epidemic in Congo in the 1960´s, the virus was 
brought to Haiti with returning workers/soldiers, and then to North America probably in the 
late 1960´s. It is believed to have circulated in the USA for around 12 years, before surfacing 
as a clinical condition when the first cases of AIDS were described in 1981. [15]  
The closely related HIV-2 has resulted from zoonotic transmission of a distinct variant of SIV 
from sooty mangabey monkeys. HIV-2 is less pathogenetic and transmissible and has mostly 
spread in West Africa. [8] 
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1.1.2 The HIV replication cycle 
 
Fig 3. The replication cycle of HIV-1. Wikimedia Commons. Jmarchn. 
HIV-1 infects cells bearing the CD4-receptor, the main receptor of the virus. This makes 
CD4+ T-cells the primary target of infection, but macrophages, dendritic cells, microglia and 
astrocytes can also be infected. [16]  
Glycoprotein 120 (gp120) on the virion surface binds with high affinity to the CD4-receptor, 
and conformation changes in the gp120 then allows for interaction with one of the chemokine 
co-receptors CCR5 or CXCR4. Structural rearrangements of gp41 then lead to fusion of the 
viral envelope with the cell membrane and subsequent HIV entry. [17, 18]  
Transmitted viral variants are almost exclusively CCR5-tropic and in early infection usage of 
this coreceptor dominates. In advanced disease, however, a switch to CXCR4 use may occur, 
but this is not obligate for development of AIDS. [19] 
When HIV-1 has entered the target cell, the RT enzyme creates a double stranded DNA-copy 
of the viral genome, that is subsequently imported into the nucleus and integrated into the 
host genome by the integrase enzyme. 
The integrated HIV-1 provirus is the template for the viral RNA transcripts, that are produced 
by the cellular RNA polymerase II enzyme. New copies of the viral genome are produced as 
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well as several different species of mRNAs that are translated into viral proteins in the 
cytoplasm. The assembly of the genome and viral proteins at the plasma membrane leads to 
budding of viral particles from the host cell. The last step to render the released virions 
infectious is the action of the protease enzyme that cleaves Gag-Pol polyproteins into 
functional mature proteins by cleavage of peptide bonds. [6, 7] 
The integration of proviral HIV-1 in the host genome builds a latent reservoir in inactivated 
and long-lived CD4+ memory cells. Even though only a few percent of integrated HIV-1 
proviral sequences are functional [16], these suffice to reignite the infection if treatment is 
discontinued. Therefore, ART must be life-long. To eradicate or inactivate this functional 
viral reservoir is one of the main focuses of HIV-1 cure research. [16, 20] 
1.1.3 Mechanisms of viral diversity   
Genetic diversity, both within-host and between-host, is a key characteristic of HIV-1. The 
molecular basis of viral diversity is mutations and recombinations of viral genomes, followed 
by selection of the most successful variants in a certain environment. The mutation rate in 
HIV-1 is extremely high, about 2 x 10-5 mutations per base per replication cycle in cell culture 
experiments, confirmed by in vivo analyses of neutral and deleterious mutations in whole 
genome deep sequencing data. [21] Mutations are caused by errors introduced by the RT and, 
to lesser degree, the human RNA polymerase II as well as by host cellular factors such as 
APOBEC-proteins that exert an antiviral effect by hypermutating viral sequences. [21, 22] 
The high mutation rate leads to production of many non-functional virions, but occasionally 
to successful mutations that improve virus fitness, and therefore are propagated through 
natural selection.  
Recombination in HIV-1 can happen when two viral variants infect the same cell, and their 
RNA progeny is co-packaged into one virion. When such a viral particle, with two 
genetically distinct RNA molecules, infects another cell, the inherent template switching of 
the RT results in a chimeric DNA-provirus. Recombination adds to genetic variability and 
can move accumulated combinations of mutations between viral variants. [23] 
Recombination is important within the context of both drug resistance development and viral 
diversity on the global level. 
1.1.4 Diversity between hosts - subtypes 
HIV-1 group M has diversified into genetic subtypes A-D, F-H, and J-K since its 
transmission from chimpanzees. [10, 24] Subtypes are defined by phylogenetic clustering of 
viral sequences and divided into sub-subtypes (e.g. A1, A2 and A6 within subtype A). 
Genetic variation within a subtype is about 8-17% and between subtypes usually 17-35%. 
Recombinations between subtypes may occur in dually infected patients and recombinant 
variants detected in at least three non-linked persons are named circulating recombinant 
forms (CRFs), e.g. CRF01_AE. Mosaic recombinants with genome fragments from four or 
more subtypes are called complex (cpx) (e.g. CRF04_cpx). Currently there are 97 CRFs 
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listed on Los Alamos HIV sequence database´s webpage (www.hiv.lanl.gov, accessed 
August 20, 2019). Unique viral sequences are named unique recombinant forms (URFs) and 
are reclassified into CRFs if found in three or more epidemiologically unlinked individuals. 
[25, 26] Most subtyping has so far been based on partial pol sequences of approximately 
1,000 bp, because such sequences are generated by routine HIV-1 genotypic resistance 
testing (GRT). The categorization of HIV-1 strains is challenged by the constant evolution of 
new variants and needs to be flexible. Today there is an increasing amount of near full-length 
genome (NFLG) data that will add information on the complexity of HIV-1 evolution, since 
analysis of larger parts of the genome detect inter-subtype recombinants and URFs with 
higher sensitivity. [27, 28]  
The different subtypes have so far been highly associated with geographic areas, probably 
due to a combination of founder effects, regional migration, population growth and 
urbanization. [26] A recent systematic review of available data shows that the patterns of 
HIV-1 diversity globally are dynamic and that the proportion of recombinants is increasing 
over time. Subtype C is the most common subtype worldwide (46.6 %), followed by B 
(12.1%) and A (10.3%). [29] Subtype C was described for the first time 1986 in Ethiopian 
patients by Prof Sönnerborg´s research group [30] and is likely to have spread from Katanga 
in Congo. Central Africa has the most diverse collection of subtypes and recombinants, 
reflecting the origin of all HIV-1 variants in this region. In east and west Africa, the epidemic 
is dominated by subtype A, and CRF02_AG and G respectively. In southern Africa, Ethiopia 
and India subtype C is found almost exclusively. [29, 31] North America, the Caribbean, 
Latin America, western and central Europe and Australia are dominated by subtype B, but 
CRFs and URFs are increasing. In eastern Europe and central Asia subtype A is most 
common, but with co-circulation of B and CRFs. [29] In this region the sub-subtype A6 
dominates. [32] In east- and southeast Asia, CRF01_AE is most common and in the Middle 
East and north Africa, subtype B is decreasing and CRFs, mainly CRF35_AD have increased 
to more than half of the infections. [29] 
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Fig 4. Worldwide distribution of HIV-1 subtypes 2010-2015. Reprinted with permission. [29] 
Since the beginning of the HIV-1 epidemic, subtype B has dominated in western Europe. It is 
still the most common subtype, but introduction of other subtypes and CRFs through 
migration and travel have resulted in increased molecular heterogeneity and unique subtype 
compositions of the HIV epidemics in different countries in western and central Europe. In 
eastern Europe the epidemic did not gain momentum until the early 1990´s, but then an 
explosive and homogenous spread of subtype A (especially sub-subtype A6) was fuelled by 
transmission in people with intravenous drug use (PWID). In more recent years it has 
expanded into the heterosexual population. [33] In the Nordic countries (Sweden, Denmark 
and Finland) subtype B is declining and the proportion of CRFs is increasing. [27, 34]  
1.1.5 Diversity within a host - viral quasispecies 
HIV-1 exists in the infected individual as a collection of viral variants called a quasispecies, 
that is constantly reshaped by evolutionary selection. In the infected individual the viral 
variability enables it to evade the immune system, develop drug resistance and escape 
vaccine strategies [23, 35, 36] Transmission and primary HIV-1 infection is in most patients 
caused by a single viral variant, and transmucosal transmission is suggested as the bottleneck 
event. [37-40] Recent data on higher viral diversity in the female genital tract than in blood in 
early infection suggests that this bottleneck event happens when infections in the cervical 
mucosa become systemic in female heterosexual infection. [41, 42] Viral variants with high 
fitness are favoured in transmission. As the founder virus replicates high viral load (VL), 
often > 1 million RNA copies/ml, is usually reached during acute infection. [23, 37, 43]  
Viral diversity in the blood then increases fast in a linear fashion, reaches a plateau and 
finally, when CD4+ T-cell counts are failing in advanced disease, both divergence from the 
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founder strain and diversity may decrease. [44]. The founder sequence is the starting point for 
the viral evolution that explores the sequence space around it, and in advanced disease the 
viral populations tend to approach a global HIV-1 consensus. In a large replicating 
population, the main limitation of genetic diversity is the fitness cost of combined mutations. 
[45] As the dominant viral variant in plasma change due to changes in selective pressure, less 
favoured variants may still be present in minority viral variants. A special feature of retroviral 
quasispecies is that viral variants will be archived as proviral sequences and can be 
resurrected in a later stage of infection. [46, 47]  
1.2 HIV-1 EPIDEMIOLOGY 
1.2.1 The state of the HIV-1 pandemic 
HIV-1 has spread successfully throughout the world through sexual transmission, 
transmission from mother to child, intravenous drug use, unclean medical practises and 
untested blood products. When the virus was identified in 1983, the pandemic was already 
established. Today, 37.9 million people worldwide are estimated to be living with HIV and 
thanks to massive efforts to improve access to treatment, 23.3 million of them are on ART. 
[1] The worldwide spread of the common viral subtypes has been retrospectively elucidated 
with phylogeography, using the phylogenetic relationships between viral sequences in a 
geographic framework. HIV-1 does not spread at random from high-endemic areas, but the 
spread is directed by geopolitical factors. [48, 49] 
 
Fig 5. The global distribution of people living with HIV in 2018. Reprinted with permission. 
https://www.unaids.org/en/resources/documents/2019/core-epidemiology-slides 
The nature of the epidemic differs between countries and populations. Key populations 
within people living with HIV (PLHIV) worldwide that are highlighted by the World Health 
Organization (WHO) include men having sex with men (MSM), people with intravenous 
drug use (PWID), sex workers, transgender people and people in prison. In 2018, an 
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estimated 54% of all new HIV infections affected individuals in these key populations or 
their sex partners. Individuals in these groups have a higher risk of HIV infection in all parts 
of the world but are also vulnerable and facing social and legal barriers to access diagnosis 
and care. In many countries with generalized HIV epidemics, these groups have not been 
prioritized. [50, 51] 
The area that is most affected by HIV-1 is sub-Saharan Africa (SSA), in particular eastern 
and southern Africa, where the epidemic is mainly driven by heterosexual transmission and 
the estimated HIV-1 prevalence in adults of reproductive age (15-49 years) in 2018 was 
7.0%. The prevalence differs in the region and is highest in South Africa (20.4%), Botswana 
(20.3%), Lesotho (23.6%) and Eswatini (27.3%). [52] The number of PLHIV is estimated to 
be highest in South Africa (7.7 million), Mozambique (2.2 million) and Nigeria (1.9 million). 
[52] Regional and national estimates of prevalence are only averages, and to understand the 
dynamics of HIV transmission breakdown of data in a location-population approach has been 
suggested. Sub-national diversities in prevalence and the importance of geographical high-
prevalence hot spots for HIV transmission have recently been demonstrated and calls for 
more customized interventions to control HIV-1 in SSA. [2, 53, 54] 
The general prevalence of HIV-1 in SSA is higher in women than in men. Women and girls 
are at higher risk for HIV infection because of gender inequalities, gender-based violence and 
in some countries policies and laws limit access to reproductive health services for minors. 
Efforts to eliminate mother-to-child transmission have been successful with 92% of pregnant 
women living with HIV in eastern and southern Africa receiving antiretrovirals during 
pregnancy, resulting in an average rate of transmission from mother-to-child under 10%. 
However, the use of single drug nevirapine in this setting has also resultated in a high rate of 
drug resistance among mothers and in the children in whom the prophylaxis has failed. [55, 
56] Other remaining issues are the high number of new infections during pregnancy that go 
undiagnosed and untreated, and that diagnosis in infants is often delayed when HIV-1 RNA 
point-of-care testing is not available (68% of infants born to HIV-positive women were tested 
within 2 months from delivery). New HIV infections and AIDS related deaths decline at the 
highest pace in the world, as a result of the roll out of ART, but the epidemic remains 
massive. [1, 52] 
The epidemic in North America, where the first cases of AIDS were diagnosed in the 1980´s, 
is closely linked to the epidemic in western and central Europe. HIV-1 was introduced in 
Europe through intravenous drug use and MSM contacts in or from USA and through 
heterosexual contacts from Central Africa. The countries with most non-European influx of 
subtype B were UK, France and Switzerland. [48, 57] The high-income countries in North 
America and western and central Europe have a high coverage of HIV-services and 
feasibility of individualized monitoring and treatment of PLHIV. MSM are still the group that 
is most affected by HIV-1 and 57% of new infections in 2017 occurred in this group. 
Remaining issues in the western world are a high rate of late diagnosis, 48% of individuals 
diagnosed with HIV-1 in the European Union and the European Economic area in 2016 had a 
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CD4+ cell count below 350 cells/µl at diagnosis. There is still widespread stigma and 
discrimination within the health care systems in Europe, creating barriers for testing and 
treatment especially for sex workers, MSM and PWID. [2]  
In the eastern European countries that were behind the iron curtain until the end of the 
1980ies and in the former USSR, the introduction of HIV-1 was delayed due to geopolitical 
isolation. In 1994 an explosive spread of a subtype A clade (sub-subtype A6) with probable 
origin from central Africa was noted among PWID in Ukraine and subsequently in Russia, 
Belarus and other countries in the area. [32, 33, 58] The HIV-1 epidemic is now large and has 
grown by 30% since 2010 with a majority of PLHIV (70%) living in the Russian federation. 
In 2017 the estimated number of PLHIV in Russia was 1 million. Harm reduction 
programmes for PWID are insufficient and people who inject drugs and their sexual partners 
are the major risk group for new HIV-1 infections. Infections in MSM are on the rise but 
testing in this group represent a disproportionally small part of all tests, related to harsh 
attitudes and policies towards same sex relations. [2]   
In Latin America, most new infections occur in MSM, but commercial sex is also an 
important transmission route. In some countries the HIV prevalence in MSM and transgender 
women is very high. [2] Latin America is identified as a “donor” of subtype B infections to 
both North America and Europe. [48] 
In South East Asia the dominating HIV-1 subtype is the recombinant CRF01_AE, and 
phylogeographic studies show that it spread from central Africa to Thailand, probably 
through heterosexual contacts. A rapidly expanding epidemic was established in Thailand in 
the early 1990ies and lead to spread to other countries in Asia as well as to Europe and North 
America. Concomitantly subtype B was introduced into the region through persons from 
USA. Thailand is still an important hub for transmission of HIV-1 and its importance is 
explained by its popularity as travel destination in combination with a large sex work 
industry. [49, 59] 
The response to the epidemic in the Asian countries is diverse. The estimated number of 
PLHIV is highest in India (2.1 million, 2017) [2], China (1.25 million) [60], Indonesia 
(640,000, 2018) and Thailand (480,000, 2018). [2] Several countries have had success in 
reducing the transmission related to sex work, but transmission among MSM is of increasing 
importance and rising. New infections and AIDS related deaths in the whole area are 
decreasing, but in Pakistan and the Philippines the epidemics are expanding and new 
infections in young people are on the rise. In both countries sex work is criminalized and 
parental consent is needed for HIV testing in individuals <18 years old. In Pakistan, same sex 
acts can lead to a death sentence. [2]  
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Fig 6. Distribution of new HIV infections 2018 globally by key population. Reprinted with 
permission. https://www.who.int/hiv/en/ 
1.2.2 The global 90-90-90 treatment target 
In 2014 the Joint United Nations Programme on HIV and AIDS (UNAIDS) stated that 
advances in ART to treat and prevent HIV infection make it possible to end the AIDS 
epidemic by 2030. [61] To concretize an intermediate goal, the 90-90-90 treatment target to 
be reached by 2020 was formulated. 
The target states that: 
• “By 2020, 90% of all people living with HIV will know their HIV status.” 
• “By 2020, 90% of all people with diagnosed HIV infection will receive sustained 
antiretroviral therapy.” 
• “By 2020, 90% of all people receiving antiretroviral therapy will have viral 
suppression.” 
To summarize, these goals would equal at least 73% of all PLHIV being on effective ART by 
2020. [62]  
A “fourth 90” has been suggested since PLHIV with viral control still experience challenges 
posed by co-morbidities and HIV-related stigma. This target would “ensure that 90 % of 
people with viral suppression have good health-related quality of life”. [63] 
The UNAIDS “Fast-track targets to end the AIDS epidemic by 2030” also contain a target of 
95-95-95 by 2030 and total elimination of HIV-related discrimination. [64] 
The target objectives are modelled on “the HIV care continuum” or the “treatment cascade”, 
with principles suggested already in 2005 to give an integrated description of HIV care 
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including diagnosis, linkage to care and retention in care and on ART as important aspects of 
successful treatment. This is an efficient tool to identify gaps in service delivery to PLHIV. 
[65, 66] WHO have recently issued practical guidelines on collection and management of 
cascade data. [67] 
The first country that reported to have achieved the 90-90-90 goal was Sweden. [68] Other 
countries in Europe that have also achieved the target goals are Denmark, United Kingdom, 
Switzerland, Germany, The Netherlands, Austria and France. [69] The global figures today 
are 79-78-86  with a resulting 53% of all PLHIV reaching the goal of viral suppression. [1] 
National and regional differences are huge and both epidemiological conditions and health 
care structures differ between countries, so responses and actions need to be customized 
nationally. Many challenges are however the same, to start with, to obtain reliable 
measurements of all the target objectives. Most countries do not have full coverage of HIV 
incidence reporting or full records on PLHIV on treatment and mathematical modelling of 
cascade data is a necessity. In low income settings VL is not measured in all patients. [67] 
1.2.3 HIV-1 in Sweden 
The general prevalence of HIV-1 in Sweden is low (0.08%). (InfCare HIV Nov 20, 2018) 
Since 1983 reporting of first AIDS and when diagnostic tests became available, HIV, has 
been mandatory and almost 13,000 accumulated cases have been reported. (Public Health 
Agency of Sweden) During the last decade, an average of 450 new cases of HIV-1 per year 
has been registered. [70] All 7,953 individuals currently under HIV care (InfCareHIV Aug 
21, 2019) are included in the national HIV database InfCareHIV, where epidemiological and 
clinical data is collected in real time. The database has full national coverage since 2009. [71] 
The first case of HIV-1 in Sweden was identified retrospectively to have been in care in 1976 
and the first AIDS case was identified in 1981 at Roslagstulls Hospital, Stockholm. Both 
individuals were heterosexually infected (Personal communication, Anders Sönnerborg). 
Retrospective analysis of HIV-1 antibodies has shown that the virus was introduced among 
MSM late 1979. [72] HIV-1 had an epidemic spread in Sweden in the beginning of the 
1980´s, first in MSM and somewhat later in PWID. The spread mainly took place in small 
groups of individuals with high-risk behaviour. When the individuals in these groups, 
estimated to some hundred PWID and less than a thousand MSM, were already infected, the 
spread decreased even before active prevention measures were in place. The heterosexual 
spread within Sweden was limited but several AIDS cases were identified during the second 
half of the 1980´s and related to migration. [73]  
In 2018, 481 cases of HIV-1 were reported in Sweden, including both entirely new diagnoses 
and migrants entering Swedish HIV-care with a previous diagnosis abroad. Sixty-four percent 
of the diagnoses were in men and the median age at diagnosis 38 years (range 1-77). In 76 
cases HIV transmission within Sweden was reported, and 39 of those were in MSM. [70] 
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The characteristics of individuals with new HIV-1 diagnoses in Sweden have shifted 
significantly over the years and migration and travel are now important factors. In 2018, 75% 
of individuals reported with HIV were born abroad.  Migrants from SSA with heterosexually 
acquired infections and migrants from Thailand are important groups and there is an increase 
in the proportion of migrant MSM amongst those diagnosed with HIV-1 in Sweden. [70] In 
the ongoing TIME-study on newly diagnosed HIV-infection in Sweden, 53% of 106 included 
MSM so far were of non-Swedish origin. (Personal communication, Emmi Andersson) 
The most common countries for HIV transmission abroad in 2018 were Thailand and Eritrea. 
[70] However it is not unlikely that persons who officially origin from Eritrea have their 
origin in Ethiopia, as a result of misclassification. Interestingly, these countries are not 
reported to have exceptionally high HIV-1 prevalence (Eritrea 0.7%, Ethiopia 1.0%, Thailand 
1.1%) [52] suggesting that migration is not a random event and that epidemiology of sub-
populations as well as the migration process itself is important when considering HIV-risk. 
An increasing proportion of individuals diagnosed with HIV-1 in Sweden have already tested 
positive for HIV-1 abroad and many are on successful ART at arrival, but this information is 
not completely captured in surveillance data and the trend is based on clinical observations.   
In individuals originating from high-endemic settings and diagnosed with HIV-1, 
transmission is often presumed to have taken place before migration to Sweden. However, a 
study using a CD4+ trajectory model to estimate time of infection concluded that 10% of 
migrants considered to be infected before arrival most likely got their HIV-1 infection after 
arrival to Sweden, and that transmissions among migrants after arrival to Sweden might be 
underestimated. [74] A similar pattern has been shown in Europe for both migrants who have 
been heterosexually infected and MSM. [75, 76] 
 
 
 
Fig 7. Reported HIV cases per route of transmission and country of infection, 2009-2018. 
Reprinted with permission. [70] 
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Preventive measures including ART have been successful in decreasing HIV-1 transmissions 
in Sweden. However, there is still transmission in the MSM group within Sweden and even 
more frequently during travel. Pre-exposure prophylaxis (PrEP) was recently introduced to 
strengthen prevention in MSM at high risk of HIV infection. Few endemic transmissions 
among PWID have been reported the last years, and harm reduction programmes including 
needle exchange are established in the major cities. [77]  
Sweden is a resource-rich country with tax financed health care. All HIV care, including 
ART prescription, is free of cost under the Swedish Communicable Diseases Act. The 
legislation also supports extensive partner tracing around new cases of HIV-1, and demands 
individuals with HIV-1 to stay linked to HIV care. [78] 
Sweden was reported to be the first country to reach the 90-90-90 target in 2017. [68] 
Analysis of the last two “90s” is reliable and based on the national database InfCareHIV. In 
2018, 98% of diagnosed individuals were on ART, and 96% of those were virally supressed. 
(Personal communication, Veronica Svedhem) However, there is still an uncertainty in the 
first “90” that is based on estimates of the proportion of undiagnosed people living with HIV-
1 in Sweden. The “fourth 90”, on quality of life in PLHIV is endorsed by the steering 
committee of the national database InfCareHIV, and the first goal is that 90% of patients 
should complete a standardized form on quality of life. (Veronica Svedhem, personal 
communication) 
A remaining issue in Sweden is late HIV-1 diagnosis and missed testing opportunities. In 
2009-2012 58% of individuals were late presenters, with CD+ T-cell counts <350/ul or AIDS 
at diagnosis, and this characteristic was associated with origin in SSA, Eastern Europe, Asia 
and the Pacific region. Of late presenting migrants, 66% had not been tested at immigration 
and half had lived in Sweden for more than a year at diagnosis. [79]  
HIV-1 transmissions related to migration and travel in combination with heterosexual and 
MSM spread within the country has resulted in a high genetic variation among HIV-1 in 
Sweden. Starting from a subtype B-dominated epidemic, non-B subtypes have emerged over 
time and today Sweden has one of the most genetically diverse epidemics outside central 
Africa with presence of all HIV-1 M group subtypes, 17 CRFs and 32 URFs in an analysis 
from 2014. [80] With NFLG sequencing even more URFs were detected, and transmission 
clusters of URFs in MSM in Sweden were discovered. A significant increase of URFs in 
Sweden was shown from both pol and NFLG analysis. [27] A retrospective cluster analysis 
of HIV-1 transmission in the Nordic countries show that 85% of active networks and large 
clusters were subtype B clusters, indicating the continued importance of subtype B for local 
transmission. [34] This makes studies on HIV epidemiology in Sweden complex and 
highlights the importance of continued investigation of transmission networks in key 
populations and migrants. 
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1.2.4 Estimating undiagnosed populations living with HIV-1 
Undiagnosed individuals with HIV-1 are at risk of progressive disease, AIDS and death and 
risk to transmit the virus to others. The UNAIDS 90-90-90 treatment target underscores the 
need to identify undiagnosed individuals to stop the spread of the virus and to treat everyone 
in need. Reliable estimates of undiagnosed populations are necessary to measure progress 
towards the target and to design and evaluate interventions. However, this is a challenge since 
general seroprevalence data is scarce in most settings. Mathematical modelling is now widely 
used to produce estimates of aspects of the treatment cascade both globally and nationally. [2, 
67] 
 
 
 
Fig 8. Visualisation of the concept of undiagnosed PLHIV (burgundy square) as a part of the 
total of PLHIV (large turquoise square) in a country. 
The first attempts to use mathematical approaches to increase the knowledge of the HIV-
epidemic were made in the late 1980´s when “back calculation” was introduced to estimate 
previous HIV incidence from AIDS incidence data and estimates of the distribution of the 
incubation period to development of AIDS. The method was used to assess the total number 
of infected individuals and the undiagnosed proportion. [81] With the introduction of ART 
that halted progress to AIDS, the method led to underestimation of the infected population. 
[82] Different statistical approaches were undertaken but there were still inherent problems in 
the method; it assumed a closed population, good quality AIDS-surveillance data and since 
AIDS incidence lags behind, estimates for recent periods were unreliable. [83]  
As the methods shifted focus from AIDS incidence data to HIV case reporting, the need for 
determination of the true date of infection emerged. [84] “Extended back-calculation” was 
developed and integrated with the BED assay, a serological method to classify recent and 
long-term infections, with HIV case reporting and data on AIDS defining events at diagnosis. 
This approach was independent from effects of ART but suffered from the disadvantages of 
the BED-assay (misclassifications of some longstanding infections as recent and subtype-
dependent results) and was dependent on reliable reporting. [85] 
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Based on the abundance of surveillance and cohort data in the United Kingdom, the HIV 
Synthesis model of HIV progression and the effect of ART was developed. It is an 
individual-based stochastic simulation model that simulates the course of infection in HIV-
positive individuals from the start of the epidemic and forward, based on population level 
data including new HIV diagnoses, CD4+ counts and ART-effects including possible drug 
resistance. Fictive individuals are modelled from infection (transmission is not modelled) and 
onwards, with parameters such as diagnosis status, CD4+ counts, ART adherence and AIDS 
diagnosis being updated every three months in the model. Model outcomes are calibrated to 
observed data. General disadvantages are that it is mathematically advanced and computer 
intensive. [86, 87]  
The back-calculation approaches were used mainly in high-income countries, where reliable 
data on AIDS diagnoses over time was available. For low-income settings, demography 
based models with less data requirements have been a way forward. [88] 
The method currently used by most countries and recommended by WHO as default for 
estimates of the total number of PLHIV is the Spectrum AIDS Impact Model. The Spectrum 
program, first put together in 1995, is based on a demographic projection model that projects 
the population by age and sex and has multiple uses in examining trends and interventions 
related to reproductive health. Modules related to factors that influence demography are 
added on, including the AIDS Impact Model. The model and the assumptions, that reflect 
current knowledge of different aspects of HIV infection and ART, are updated regularly 
under the guidance of the UNAIDS Reference Group on Estimates, Modelling and 
Projections. [67, 89, 90] The main input to estimate HIV prevalence and the number of 
PLHIV in generalized epidemics is the prevalence in pregnant women at antenatal care 
centres combined with data from household/key population surveys and ART- and prevention 
of mother-to-child transmission (PMTCT) programmes. In epidemics concentrated in key 
populations, serosurveys in these populations and estimates of their size, or HIV case 
surveillance in combination with AIDS-related mortality is used. Spectrum estimates are 
considered robust, and data quality and coverage can be considered in the process. 
Uncertainties of the estimates are displayed as 95% plausibility bounds. The limitation is that 
as for any model, input data must be representative for the modelled population to produce 
reliable estimates. [2, 67, 91]  
To address the need to make estimates of the care cascade including the undiagnosed 
proportion of HIV in Europe, the Stochastic Simulation of Outcomes of People with HIV In 
Europe in EuroCoord (EuroCoord-SSOPHIE project) was formed in 2011. The HIV-1 
epidemics in European countries are diverse, but often concentrated to key populations, and 
with important influence of migration. The goal was to develop an improved individual-based 
model of HIV to make estimates of European PLHIV based on surveillance and clinical data. 
[92]. The resulting model (presented more in detail in the methods section 3.3.2) is a 
development of the HIV Synthesis progression model and is designed to model key 
populations and other risk groups separately and attempts to model the effect of migration 
from high-incidence countries in SSA. [87, 93] 
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European Centre for Disease Prevention and Control (ECDC) has designed a HIV modelling 
tool (described more in detail in the methods section 3.3.3) that is under continuous 
development and accessible without cost. An incidence model requiring less data than the 
above described and a back-calculation model only requiring the number of HIV/AIDS 
diagnoses stratified due to CD4+ T-cell counts during at least one year, are provided. [94, 95]  
1.2.5 Estimates of undiagnosed populations in Sweden 
The first estimates of undiagnosed PLHIV in Sweden were based on back calculation and 
made by the Swedish Institute for Infectious Disease Control (now Public Health Sweden) in 
1998. The estimated number of undiagnosed MSM in 1986 were 400-500 individuals, as 
many as the diagnosed patients. The number of undiagnosed individuals was estimated to 
have declined to no more than 200 in the 1990´s. [73] A study of the Nordic countries 1977-
1995 using HIV and AIDS surveillance data in a back calculation based model estimated the 
proportion of undiagnosed HIV infections in MSM in Sweden to be 19% in 1995. [96] 
When the Synthesis model (described in 1.2.4) was applied to European surveillance data 
from 2005 the proportion of undiagnosed PLHIV 2006 within EU was estimated to be 30%,  
50% in the whole WHO European Region and the proportion in Sweden was estimated to 12-
20%. [97] A new analysis based on surveillance data 2003-2015 and using the incidence 
method of the ECDC HIV modelling tool, estimated that 15% of PLHIV in Europe were not 
diagnosed in 2015, but no country-specific estimates were made. [98] 
Our efforts (Paper III) to estimate the proportion of undiagnosed PLHIV in Sweden 2013 
with established methods resulted in unexpectedly high estimates: 26% (n=2,100; 90% 
plausibility range [PR] 900-5,000) with the SSOPHIE method and 21% (n=2,013; 95% 
confidence interval [CI] 1,831-2,189) with the incidence method of the ECDC HIV 
modelling tool. Our conclusions were that we need better data on migration and further 
development of methods to obtain reliable estimates of the diverse Swedish HIV-1 epidemic. 
[99] 
The Swedish Public Health Agency reported an estimate of 10% undiagnosed patients 2015 
based on surveillance data, that supported the achievement of the 90-90-90 target in 2015. 
[68] This preliminary estimate was produced by back-calculation from surveillance data and 
serosurveys in blood donors. However, blood donors are not representative of the general 
population as they are selected to have low risk for blood-borne infections. (Maria Axelsson, 
personal communication) 
A novel approach relies on biomarker-based estimates of time to diagnosis in newly 
diagnosed individuals and can discriminate between infections within and outside the country 
by adding migration and surveillance data to a Bayesian model. This method estimated the 
undiagnosed proportion of PLHIV in Sweden to be 816 individuals in 2015, a number that 
equals 10.8% (95% CI 10.3-11.4%) of PLHIV. [100] 
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1.2.6 Estimating time to HIV-1 diagnosis 
The long clinical “latency” period from infection to symptomatic disease in HIV-1 infection 
often makes it hard to assess when a patient was infected. In most cases, anamnestic and 
clinical information is not enough. Laboratory confirmed primary HIV-infection and 
seroconversion data with narrow intervals are the most reliable data but are sparse. Patients 
with low CD4+ T-cell counts are more likely to have been infected for a long time, but since 
the rate of CD4+ decline is variable this is not completely reliable. [101] During primary HIV 
infection the CD4+ T-cell counts are most often low during the first month and pose a risk of 
misclassification of the infection as long-standing. [102]  
To estimate HIV-1 incidence and for higher accuracy in addressing undiagnosed PLHIV, 
good estimates of time to diagnosis are helpful, and although much effort has been put into 
this field of research, no method is yet reliable at the individual level.  
Algorithms based on serological assays have been widely used for epidemiological purposes 
and can discriminate between recent and chronic HIV-1 infection. [103, 104] There are three 
different approaches of serological assays; measurement of the level of HIV-1 antibodies 
("detuned assays", not widely in use today), measurement of the proportion of HIV-1 specific 
IgG related to the total IgG (BED capture enzyme immunoassay), and measurement of 
avidity of HIV-1 antibodies (Limited Antigen Assay (LAg)). A disadvantage of the BED 
assay is that it misclassifies a proportion of long-term infections as recent and that a 
calculation of false-recent rates specific to the studied population is required. Furthermore, 
HIV-1 subtype influences performance and this is problematic in non-subtype B and 
epidemics with mixed subtypes. Usage of BED results can be maximized with addition of a 
mathematical model that allows assessment on a longitudinal scale instead of just a 
dichotomous result. [105] LAg assays are more sensitive but can be affected by tuberculosis 
infection and misclassify HIV-1 subtype D.  [106-108] Advantages of serological methods 
are that they are relatively cheap and can be made on serological samples or dried blood spots 
without any additional data required. [109] High false recent rates in individuals on ART can 
be reduced by introducing viral load as an additional parameter. [110] 
An alternative approach is to use the increase of viral diversity during infection as a marker of 
time since transmission. In pol sequences collected for routine genotypic resistance testing by 
Sanger sequencing this is represented by an increase in the proportion of ambiguous (mixed) 
base-calls. The method can discriminate between recent and long-term infection in various 
subtypes if a dichotomous cutoff is used, but weaknesses are misclassification of long-
standing infections with decline in diversity, and that it does not work well in individuals 
infected with more than one viral variant. Methodological variations such as different 
thresholds for calling mixed bases need to be considered. [111-113]  
Next-generation sequencing/High-throughput sequencing (NGS/HTS) with deep sequence 
analysis of viral variants can assess diversity with higher accuracy, and potentially overcome 
the obstacle of multiple founder strains in recent infection. [114-116] This approach gives 
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possibility to assess the time of infection on a continuous scale rather than dichotomous, 
increasing the usefulness beyond incidence assays. The increased sensitivity is based on 
detection of minority viral variants below the detection limit of Sanger sequencing. Different 
parts of the genome have been used for assessment of viral diversity. [114, 116] Puller et al. 
found an optimum in 2,000-3,000 bp of pol, with a linear increase of viral diversity in the 
third position of the codon, at least 8 years after infection. The precision of estimates was +/- 
one year in long-time infection and slightly lower in more recent infection. [116] This was 
corroborated on a larger material (n=313) from the Swiss cohort, although mainly subtype B 
sequences. A direct comparison to mixed base-calls in Sanger sequences was made and 
clearly stated the advantage of the NGS-based analysis. [114] Another study chose the env 
gene and integrated the approach with an algorithm to calculate HIV incidence. [117]  
 
 
 
Fig 9. Diversity in pol (average pairwise distance) as a function of time since infection (TI) in 
eleven individuals with well-defined time of infection and sequential naïve samples. 
Reprinted with permission. [116] 
Even though CD4+ T-cell counts at diagnosis do not suffice for estimating time from 
infection, they carry useful information and performance of estimates can be improved by 
mathematical modelling. A CD4+ T-cell decline trajectory model that is based on modelling 
of the CD4+ T-cell slope from infection to diagnosis with consideration of effects of patient 
age and region of origin on CD4+ T-cell decline has been developed. [74, 118] 
To improve estimates and address weaknesses of individual assays and biomarkers, 
algorithms combining parameters have been suggested. [100, 108, 119] A recent publication 
showed that the optimal combination for incidence estimates in subtype C in African women 
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was a combination of two serological avidity assays and VL. However, viral diversity was 
not tested as part of the algorithm. [120] 
So far there are no published data on combination assays including viral diversity measured 
with NGS. Usefulness of algorithms depends not only on their performance, but also on 
availability of data. With increasing use of NGS for GRT worldwide, estimates based on viral 
diversity will be more accessible. Even though NGS estimates viral diversity with high 
resolution, the issue with multiple founder viruses remains [114], but can potentially be 
addressed with serological assays, that have discriminatory strength in early infection.  
1.2.7 Estimating country of HIV-1 infection 
In settings where migration and travel are important factors for HIV-1 epidemiology, it is 
important to distinguish between domestic and foreign transmissions. Both local infection 
control interventions and modelling efforts of HIV seropositive populations depend on 
correct information on country of infection. In 2017, 41% of individuals reported with HIV 
infection in the EU/EEA were not born in the reporting country. [121] Sweden reports the 
highest proportion of migrants (75% 2018) among newly diagnosed individuals in Europe. 
[70] A systematic review of post-migration HIV acquisition in Europe underscores the 
clinical and epidemiological relevance of HIV infections occurring in migrant groups in their 
new country of residence, and the need for surveillance and prevention initiatives designed 
for these populations. [76] Infections acquired post-migration are not necessarily acquired in 
the country of residence, but still possible to prevent by targeted national initiatives. 
To collect reliable data on country of infection, doctors´ reports are not sufficient, since they 
tend to underestimate infections after arrival. To improve estimates, combinations of methods 
to estimate time to diagnosis, collection of dates of arrival and phylogenetic approaches have 
been attempted. [74, 75, 118]  
The French PARCOURS study assessed that the proportion of post-migration acquisition of 
HIV in PLHIV from sub-Saharan Africa living in France was at least 35%, based on real-life 
data in combination with CD4+ T-cell modelling. [122] A British study using CD4+ T-cell 
modelling tripled the estimate of domestic infections in foreign born to 33% compared to the 
estimates by clinical reports (11%). [118]  
A study on migrants in Sweden diagnosed with HIV-1 during 1983-2013 estimating time to 
diagnosis with a CD4+ T-cell decline trajectory model and comparing the results to date of 
arrival, also suggested that domestic infection in migrants was more common (19%) than 
indicated by doctor´s estimates (12%). Further analysis with phylogeny of pol sequences 
corroborated the results. [74] 
The aMASE study used a Bayesian approach on epidemiological data integrated with CD4+ 
T-cell counts and viral load trajectory data on migrants diagnosed with HIV in nine European 
countries. In this cohort, acquisition of HIV post-migration was 63%, with the highest 
proportion, 72%, in MSM. Individuals with origin in Latin America or the Caribbean were 
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infected after arrival in 71%, and 45% of migrants from SSA were infected post migration. 
[75] 
1.3 HIV-1 ANTIRETROVIRAL THERAPY 
1.3.1 Development of antiretroviral therapy 
One of the first antiretroviral therapy trials ever performed was with the drug foscarnet at 
Roslagstulls Hospital, Stockholm, in 1985-1986. Later it was shown that foscarnet had a 
pronounced antiviral effect on HIV-1 with declining levels of HIV antigen [123] and HIV 
RNA during therapy. [124]  Also novel approaches like a small peptide [125] and alpha-
interferon were tested. [126] Antiretroviral therapy for HIV-1 on a larger scale was first 
introduced in 1986 with the nucleoside analogue zidovudine (AZT), and reduced mortality 
significantly during short-course studies [127-129]. However, the effect on survival 
decreased after 15-18 months of therapy and in 1989 a phenotypic assay revealed AZT-
resistance in virus isolated from patients treated for more than six months [130]. The same 
pattern of mutations in the RT was found in all resistant strains, and evidence of the 
sequential accumulation of the mutations was presented. [131] 
The need for combination therapy for HIV-1 to avoid development of resistance was 
recognized early, based on the properties of the virus and empirical evidence. Through 
studies of the HIV-1 life-cycle potential targets for antivirals were identified and drugs 
targeting different steps in the viral replication were developed during the early 1990´s; 
additional nucleoside RT inhibitors (NRTI), non-nucleoside RT inhibitors (NNRTI) and 
protease inhibitors (PI). However, no drug or drug combination succeeded in durably 
suppressing VL, and signature mutations for respective drug and/or drug class were detected 
in resistant strains. [132, 133] It was shown that sequential therapy favoured development of 
multidrug-resistant virus both in vitro and in vivo. [134, 135]  
In 1996, a combination of the most potent drug class, PI, with two NRTIs, proved to be 
effective in durably reducing VL and mortality in AZT-experienced patients. [136-138] 
Another breakthrough was the identification of HIV-1 RNA quantification in plasma as a 
valid marker for treatment efficacy and prognosis for patients on treatment. [139, 140] 
Accumulated resistance mutations leading to multi-drug resistance were a major issue in 
patients with treatment experience. The need for pre-treatment and treatment-failure GRT 
was identified, and with technical achievements sequencing of viral genes was suggested as a 
feasible method. [141] 
 In 1996 a standard-of-care with two NRTIs combined with a PI or NNRTI backbone was 
established. Viral suppression under 500 copies HIV-1 RNA/ml was identified as a treatment 
goal but still not reachable in all cases. [142-144] The addition of ritonavir-boosting of PIs 
[145] and further development of antivirals has resulted in modern ART regimens that 
suppress VL to undetectable levels with a low pill-burden and much less side-effects. With 
the development of more sensitive HIV RNA quantification assays the cutoff of 
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“undetectable virus” has now been moved to 20 or 50 copies/ml, depending on the assay. 
[146] Today, seven classes of antivirals targeting different parts of the HIV-1 life cycle are 
available; NRTI, NNRTI, PI, integrase strand transfer inhibitors (INSTI), CCR5-inhibitors, 
fusion inhibitors and post-attachment inhibitors. The three last drug classes inhibit entry into 
the cell and are seldom used. A new class, the capsid inhibitors, is in early clinical trials and 
has shown high potency and promises to be useful as a long-acting drug. [147]  
INSTI are an increasingly used alternative to NNRTI and PI since registration of the first 
compound of this class in 2007. Besides a rapid decline in VL at treatment initiation, INSTI 
also have the benefits of a low frequency of side effects and drug-drug interactions. [148] 
However second generation INSTI dolutegravir (DTG) and bictegravir (BIC) are still under 
investigation for association with an increased frequency of neural tube defects in pregnancy 
[149] and weight gain has been associated with DTG. [150] 
 
Fig 10. Schematic presentation of the impact of different classes of antivirals on the HIV-1 
replication cycle. Wikimedia Commons. Thomas Splettstoesser (www.scistyle.com) 
1.3.2 Monitoring of treatment 
Quantitative HIV-1 RNA measurements in plasma as a measure of viral suppression and 
CD4+ T-cell counts in blood to monitor immune reconstitution have proven individual and 
combined value in predicting outcomes in PLHIV on ART. [140, 151] Effective ART usually 
reduces the VL in plasma below detectable levels of sensitive assays (<20 or <50 copies/ml) 
in 8 to 24 weeks, and maintains viral suppression thereafter.  
Insufficient drug effects due to antiviral resistance or suboptimal drug concentrations can lead 
to virological failure, commonly defined as repeated HIV-1 RNA measurements >200 
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copies/ml. Reasons for insufficient effect of modern ART regimens are suboptimal 
adherence, decreased uptake from the gut or drug-to-drug interactions. Identification of HIV 
RNA in plasma during ART should lead to evaluation of the current regimen, including 
adherence, and the possible need for regimen switch and/or GRT. [146, 152] Continuation of 
a failing regimen will lead to accumulation of resistance mutations and further loss of 
regimen efficacy, also in drugs with a high genetic barrier such as DTG and boosted PIs. 
[153, 154] A meta-analysis has shown that individuals with virological failure that had not 
been frequently monitored with VL had more resistance mutations at time of failure than 
those who were closely monitored. The probable reason is that delayed detection of 
virological failure allows for further development of resistance. [155] Continuous monitoring 
of VL during ART ascertains that individuals get the best treatment effect and that the risk of 
transmitting HIV-1 is negligible when undetectable levels of HIV RNA in plasma are 
achieved. [152] “Blips” are occasional events of detectable low-level viremia with 
subsequent return to undetectable levels in an individual with viral suppression, and are 
usually not related to virological failure or development of drug resistance, but rather reflect 
stochastic variations in actual VLs and VL measurement precision. [156] However, they can 
be predictive of later virological treatment failure. [157] There is still controversy on the 
significance of persistent low-level viremia 20-200 copies/ml, but evidence exists that 
resistance can emerge even at this levels under the selective pressure of ART. [152, 158-160] 
Viral blips and low-level viremia have been associated with slower decay of HIV-1 reservoirs 
under ART, something that may be of importance in HIV-1 cure efforts. [161] 
1.3.3 Clinical impact of HIV-1 subtype 
Several studies have suggested that HIV-1 subtype influences virulence and disease 
progression in naïve individuals, but the evidence is conflicting. Association of subtype with 
ethnicity, route of infection and other epidemiological factors is a potential bias. [162-166]  
In VL monitoring and GRT, subtype-related viral diversity is a challenge due to variation in 
targets for PCR and sequencing. Many assays were originally designed for subtype B, 
resulting in non-quantification or sub-quantification of strains with differences in target 
sequences. Local subtype representation needs to be considered when introducing new 
laboratory assays, and in interpretation of conflicting laboratory results. [167-170] 
Today, there are no subtype-specific recommendations on ART regimens. Potential subtype-
related differences in efficacy of antiretrovirals are of major interest when extrapolating ART 
efficacy results from studies mainly on subtype B to settings where other subtypes are 
dominant. 
A review of available studies showed small differences in individuals on ART but there were 
subtype-specific differences in resistance mutation patterns in treated populations. [171] In a 
Swedish study from 1998 - 2002, where most patients were treated with ART regimens with 
unboosted PIs, the outcome in individuals with African origin was inferior, but no relation to 
HIV-1 subtype was proven. [172] A recent comparative study in the Swedish InfCareHIV 
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cohort showed higher risk of both primary and secondary virological failure in subtype C 
than subtype B when boosted PI were used. Molecular dynamics structure simulation and 
docking analysis of the subtype C protease, suggested that the binding of PIs is weaker in 
subtype C due to naturally occurring polymorphisms and that this explains a weaker 
treatment effect. [173] A clinical study from US points in the same direction. [174] In 
addition, a PYxE insertion in Gag-p6 has been found to increase the viral fitness of subtype C 
strains and also be associated with an increased risk of failure on boosted PI therapy. [175-
178] Results from a clinical study have also indicated that CRF 02_AG strains are inherently 
less sensitive to boosted PIs than subtype B strains. [179] Also second generation NNRTIs 
etravirine and rilpivirine have shown lower potency in subtype C strains in in vitro 
experiments. [180, 181] 
INSTI have been introduced in low- and middle-income countries (LMIC) recently and real-
world efficacy data on other subtypes than B are sparse. Indications of significance of 
subtype-related polymorphisms in combination with pre-treatment findings of major INSTI 
mutations in minority viral variants in subtype C strains from Ethiopia points to a need of 
further investigations of subtype-related differences in efficacy. [182-184] Failures on the 
long acting INSTI cabotegravir in a clinical study have recently been associated to sub-
subtype A6 and possibly to the polymorphism L74M/I. [185] 
1.4 HIV-1 DRUG RESISTANCE 
1.4.1 Genetic barriers to resistance 
All modern ART combination regimens block viral replication and maintain long-term viral 
suppression if drug concentrations suffice and no pre-treatment drug resistance (PDR) is 
present. However, regimens differ in robustness if adherence fails. [154] The risk of 
resistance development is decreased with drugs with high potency and a high genetic 
barrier. The antiretroviral drugs and drug classes have different barriers to resistance, 
depending on how many mutations in the viral genome that are needed to lead to clinically 
significant resistance and the consequences for the virus of the mutations. [160] So far, no 
drug class is robust enough to use for monotherapy, but regimens with two drugs have been 
suggested and are already in clinical use in some settings. However, the standard of care is 
still three antiretrovirals in combination. [186] 
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Fig 11. Potency vs genetic barrier to resistance in important antiretrovirals for HIV-1 
treatment. NRTI (FTC, 3TC, ABC, TDF, DDI, ZDV(=AZT), d4T), NNRTI (EFV, NVP, 
ETR), PI (ATV/r, LPV/r, DRV/r) INSTI (RAL, DTG), Fusion inhibitor ENF and CCR5-
inhibitor MVC. [160] Reprinted with permission. 
In drugs with a high genetic barrier, resistance development requires several steps, where 
the virus has opportunity to replicate under insufficient, but still selective, concentrations of 
the drug for a long time. This favours selection of variants with drug resistance mutations, 
and in the following steps drug resistant variants may develop both increased resistance and 
compensatory mutations that increase viral fitness. Due to viral diversity, many single drug-
resistance mutations are probable to exist pre-treatment by chance, but this is not the case 
for combinations of resistance mutations. [187]  
In the example of boosted PIs, that generally have a high barrier to resistance, the 
resistance-causing "major" mutations usually decrease the fitness of the virus and are 
followed by "minor" mutations that restore the fitness of the resistant virus to make it more 
competitive. Minor mutations are frequently wildtype variants, i.e. polymorphisms, in some 
subtypes of HIV-1. [188-190]  
Important examples of drugs with a low genetic barrier are the widely used first generation 
NNRTIs efavirenz (EFV) and nevirapine (NVP) and NRTIs emtricitabine (FTC) and 
lamivudine (3TC) as well as the INSTIs raltegravir (RAL) and elvitegravir (EVG). For 
these drugs, one mutation is enough to create a virus with high resistance. This makes these 
drugs particularly unforgiving to insufficient drug concentrations, since highly resistant 
variants will readily be selected once the virus is allowed to replicate under drug pressure. 
[191] The accompanying drugs are also endangered if the regimen is not switched 
promptly. [192]  
For other NRTI drugs, the resistance is complex in that different evolutionary pathways 
towards high-grade NRTI resistance exist, and that patterns of mutations affect the 
individual NRTIs differently. [187] The two alternative pathways of thymidine analogue 
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mutations (TAM), induced by the early NRTIs AZT and stavudine (d4t) exemplify this. 
[193] Viral subtype is another factor that influences how resistance patterns emerge during 
virological failure, depending on differences in the original viral sequence. [194, 195] 
Recently a new RT inhibitor, 4-ethynyl-2-fluoro-2-deoxyadenosine (EfdA) has been found to 
have a higher in vitro genetic barrier to drug resistance that earlier NRTIs. [180]  
INSTI are very potent drugs that give rapid viral decline. The first generation INSTI (RAL 
and EVG) has the disadvantage of a low genetic barrier [196], but the second generation, 
dolutegravir (DTG), bictegravir (BIC) and cabotegravir, were developed to have a high 
genetic barrier. [197] As in the case of PIs, several evolutionary steps (mutations and 
selection) are required for development of resistance. However, monotherapy has failed in 
clinical trials and at least one potent companion drug is necessary. [198] 
1.4.2 Acquired drug resistance 
Acquired drug resistance in HIV-1 infection may develop when viral suppression is 
insufficient in an individual on ART, usually due too poor adherence or pharmacological 
interactions. Minority viral variants harboring resistance mutations will then appear due to de 
novo mutations and can be selected by evolutionary pressure. Their ability to replicate in the 
presence of ART will lead to their enrichment in the major viral population. Drugs with lower 
genetic barriers to resistance are usually affected first, and by switching to second line 
treatment promptly, resistance to accompanying drugs may be prevented. Prolonged viral 
failure may lead to multiclass drug resistance. [199, 200]  
In many cases, cross-resistance is of clinical importance, meaning that other drugs of the 
same class are compromised by the acquired mutations. Cross-resistance is not always 
absolute and differs between drugs and drug classes. In drug development (i.e. NNRTI and 
INSTI) care has been taken to try to avoid cross-resistance between first generation drugs 
and following compounds. Within the NRTI-class, a mutation can decrease or increase 
antiviral effects of different NRTIs (i.e. M184V reduces sensibility to 3TC and FTC but 
increases the effect of tenofovir (TDF)). [160, 201] 
The viral subtype has some impact on the development of certain drug resistance mutations, 
for example V106A is more common in subtype B and V106M in subtype C, in response to 
failing NNRTI regimens. Subtype C has a higher tendency to develop K65R that confers 
NRTI-resistance, especially to TDF. [160] 
The integration of resistant proviruses in the genome of CD4+ T-memory cells creates an 
“archive” of resistance mutations and “treatment/resistance history” needs to be considered in 
individuals restarting or switching ART regimens. [200, 202] 
1.4.3 Transmitted drug resistance 
Drug resistant variants of HIV-1 may be transmitted from a patient with acquired 
resistance, and further on from one naïve person to another. Transmitted drug resistance 
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(TDR) in HIV-1 was first described in 1993 [203-206], but anticipated already when the 
first AZT-resistant viral strains were found [131]. TDR can hamper the success of first-line 
ART if not accounted for in regimen design. [207, 208]  
The continuous reshaping of the viral quasispecies leads to reversion of less fit resistant 
viral variants after transmission to a naïve individual. If they only exist in minority viral 
variants they will not be detected by routine population based sequencing but may still be 
of clinical importance. Depending on their impact on fitness, there is variation in 
persistence of different drug resistance mutations in population-based sequences. A cohort 
study of ART naïve individuals with TDR showed that among NRTI-mutations, M184V 
reverted quickly with a median time of one year, while M41L and other TAMs were 
detected for much longer. Mutations in position 215 did revert, but the revertant variants 
were conserved. Reversion of NNRTI mutations was faster than for the TAMs, K103N had 
a median time to loss of 3.7 years. [209]  
A consensus cut off ≤180 days from diagnosis has been used for sampling for resistance 
testing in TDR studies to increase sensitivity, but the date of infection, when reversion 
probably starts, is seldom known.  
In vitro studies show that some resistance mutations decrease the replicative fitness of the 
virus (e.g M184V, K65R and T215Y), but others do not affect fitness as much (e.g L90M, 
Y181C, D67N, L210W). Whether the same effect on transmission fitness applies has been 
uncertain. [210] Several approaches have been applied to specifically study transmission 
fitness; comparisons of mutation prevalence in treated and untreated patients from the same 
epidemic [211], relative tendency of strains with and without resistance mutations to form 
clusters in a molecular transmission network [210] and a phylodynamic approach that 
assessed transmission rates of wild type versus resistant strains. [212] There is consensus 
from at least two of these studies on that the NRTI mutations K70R, M184V and T215Y 
have lower transmission fitness, that M41L, the T215 reverts, and the important NNRTI 
mutation K103N do not hamper transmission and it is also indicated that the PI mutation 
L90M might increase transmission fitness. 
In Europe and the US, transmitted TAMs and NNRTI-mutations are frequently related to 
clonal spread from ART-naïve individuals. [210, 213-217]  
In contrast, in SSA TDR has been suggested to be more closely related to spread from 
individuals on failing regimens, since clustering patterns are uncommon in studies. [218] 
However, sampling of a small fraction of individuals could underestimate spread of TDR 
from naïve individuals. [217] Findings from a recent study in Ethiopia support that TDR 
from naïve individuals is important also in SSA; a phylogenetic sub-cluster with the 
NNRTI mutation G190A was traced from 2003 – 2010. [219] 
So far, transmitted resistance to INSTI is uncommon, and baseline integrase GRT is not 
generally recommended in most guidelines although this is routinely performed in certain 
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areas such as France and Stockholm (Personal communication, Anders Sönnerborg). 
However, case reports indicate that major INSTI mutations E138A, G140S, Q148H and 
N155H can be transmitted and the first report of transmitted high-level resistance to all 
INSTIs was recently published. [220-222] 
1.4.4 Pre-treatment drug resistance 
Pre-treatment drug resistance (PDR) is any drug resistance in individuals about to initiate 
first-line ART. In most settings this means a combination of individuals who are newly 
diagnosed with HIV-1 and of those who have been on treatment before but stopped. PDR 
measures thus a combination of TDR and acquired drug resistance. It is still important to 
differentiate the types of drug resistance, but lack of medical history often makes it hard to 
differentiate TDR from acquired resistance, especially in migrants. PDR is a pragmatic 
concept that mirrors the clinical resistance situation. [199, 223] 
1.4.5 Resistance testing 
Testing for HIV-1 drug resistance (HIVDR) can be performed by phenotypic or genotypic 
methods.  
Phenotypic testing assays are technically more demanding and more expensive. They 
measure the growth of HIV-1 in a cell culture under different concentrations of a certain 
antiviral, to determine the median inhibitory concentration (IC50) and the fold increase of IC50 
between the tested strain and a sensitive reference strain. When phenotypic assays were first 
developed, HIV-1 isolates from a patient were cultured, leading to a risk of the results not 
being representative of the in vivo strain. Replacement with recombinant assays where a pol 
sequence from the plasma virus is inserted into a laboratory HIV-1 strain, has improved the 
technique. These methods are best applied in studies of effects of new mutations/new drugs 
or in extremely complex clinical situations as a complement to GRT. Phenotypic testing of 
new generations of drugs renders vital information on cross-resistance due to mutations 
selected by compounds from the same drug class. [199, 224]  
GRT to NRTIs, NNRTIs and PIs at baseline and at virological failure is an integrated part of 
HIV-1 care in high income settings. The routine method is still mostly population based 
(Sanger) sequencing of pol with commercial assays or in-house methods that target a pol 
fragment, including relevant parts of RT (for NRTIs and NNRTIs) and protease (for PIs). The 
sequence is then analyzed for presence of known drug resistance mutations (DRM). 
Resistance testing for integrase requires sequencing of an additional fragment of pol and 
international guidelines only recommend it in failure on INSTI regimens and if TDR to other 
drug classes is found. [199]  
A general limitation of Sanger sequencing is that only resistant variants representing 
approximately 20% of the viral population are detected. [37, 225-228] With the advent of 
NGS/HTS viral variants down to 1% can be reliably determined, increasing sensitivity of 
detection of drug resistant variants that constitute a minor proportion of the virus population 
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but potentially decreasing the clinical specificity of findings. So far there is some evidence 
that NNRTI mutations down to 5% may be clinically relevant, since presence of minority 
viral variants of NNRTI-resistant virus has been reported to increase the risk of virological 
failure. [229-231] For the other drug classes a conservative reporting of variants 15-20% is 
suggested since there is no evidence of a benefit of reporting lower proportions of resistant 
variants. [229, 232] This is suggested by, among others, Inzaule et al. who base their 
recommendations on a large, prospective case control study in SSA. [229] In contrast, a study 
by Derache et al. from South Africa showed that NNRTI mutations alone had no effect on 
time to viral suppression on efavirenz-based ART neither above the 5% nor 20% threshold. 
However, NRTI and NNRTI mutations in combination prolonged the time to viral 
suppression when a 5% detection level was applied. The discrepancy to other studies is 
suggested to depend on the higher potency of a TDF/FTC containing backbone than of the 
thymidine analogue backbone that dominated in other cohorts. [233] A Swiss study 
demonstrated that viral suppression was obtained in individuals on boosted PI and 2 NRTIs 
despite presence of the NRTI-mutation M184V in minority variants. [234]   
A practical advantage of NGS/HTS resistance testing is that a larger fragment of 3,000 bp can 
be sequenced and therefore only one test is required to also obtain INSTI resistance results. 
So far there is no convincing evidence that pre-treatment minority viral variants with INSTI 
drug resistance mutations are of clinical importance although very little data are available. 
[235] 
NGS/HTS resistance assays generate massive amounts of data and a bioinformatic pipeline is 
needed to process sequencing data and produce resistance reports for clinical purposes. 
Several non-profit and commercial pipelines handling HIVDR HTS data are available, with 
varying demands of bioinformatic expertise for the user. In 2018 a multidisciplinary meeting 
resulted in “the Winnipeg consensus” with recommendations to harmonise HIVDR testing 
with NGS. [232] 
Most evidence for associations between DRMs and clinical outcomes is generated from 
plasma samples, hence that is the material of choice. [199] However, dried blood spots (DBS) 
have been successfully used in LMICs and facilitate handling and shipping of samples to 
centralized laboratories since no cold chain is required. [236] Also a “split” procedure has 
been suggested where the amplification from plasma is done locally and the product sent to a 
central laboratory for sequencing. [237] To study archived resistance mutations in individuals 
with complex treatment histories, sequencing of proviral DNA in peripheral blood 
mononuclear cells (PBMC) has been suggested, but the clinical usefulness remains to be 
proven. [160] 
The analysis of sequences generated for resistance testing is complex and the most common 
method is to apply a rule-based algorithm such as the Stanford HIV Drug Resistance 
Database, French National Agency for Research on AIDS and Viral Hepatitis, Rega, or HIV 
Genotypic Resistance-Algorithm Deutschland. In bioinformatic pipelines for NGS/HTS 
HIVDR, an algorithm needs to be part of the pipeline. The algorithms integrate information 
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from in vitro experiments, sequencing of HIV-1 from individuals on failing regimens and 
clinical studies with expert opinions to formulate a set of rules on the effects of certain 
mutations and combinations of mutations. The reports produced state susceptibility or level of 
reduced susceptibility to the commonly used drugs. [199, 238] The IAS-USA Drug 
Resistance Mutations Group compiles new data in a list that is updated regularly. [189]  
Machine learning approaches are an alternative to the rule-based algorithms. [199, 239-244] 
They have the potential of integrating the genotypic data with other parameters of relevance 
for treatment success and hence produce more individualized predictions but are not widely 
used in the clinic today. In a head-to-head comparison between a predictive engine and 
“resistance experts”, the machine learning was found to be a better predictor of which drugs 
to choose after a virological treatment failure than the experts. [245]  
To implement resistance testing for clinical purposes in LMICs, where sequencing facilities 
are limited, point-of-care testing with rapid reporting of the most important mutations has 
been suggested. A major challenge in design of such assays is the sequence variation 
surrounding the drug-resistance positions of interest. [246, 247] Development of 
methodology for point-of-care testing of specific HIVDR mutations include PCR based 
approaches such as oligonucleotide ligation assays, multiplex allele specific assays and pan-
degenerate amplification and adaptation, but also methods based on isothermal amplification. 
Implementation of any assay as part of ART programmes in resource limited settings is 
dependent on adequate training in handling and interpretation of the test, quality assurance 
programs and a functioning infrastructure including reliable electricity. [248] 
1.4.6 The global perspective 
In high-income settings, ART regimens are individually designed to have a low pill-burden, 
minimized side-effects and the choice of regimen is guided by baseline GRT to detect PDR in 
PR/RT, increasingly often also in IN. Therapy is monitored with HIV-1 RNA quantification 
and CD4+ T-cell counts, to timely detect virological failure and address adherence issues or 
emerging drug resistance. PDR can be handled clinically although pre-exposure (PrEP) and 
post-exposure (PEP) prophylaxis to HIV-1 may still be compromised. 
In low- and middle-income settings on the other hand, an individualized approach is usually 
too costly and logistically challenging to reach all in need of treatment. [154] The public 
health approach to ART was introduced by WHO in 2006 and made roll-out of treatment 
feasible by simplified and harmonised ART regimens. A standardised first-line regimen with 
EFV (NNRTI), TDF and FTC (NRTIs) has been recommended to all adult patients from 
2016. VL monitoring was introduced in WHO guidelines in 2016 but is still not widely 
available or has long turn-around time from sampling to result reporting. The disadvantage of 
an NNRTI-regimen, which has a low genetic barrier to resistance in combination with limited 
access to VL monitoring is that patients will stay on a failing regimen longer because switch 
to second line will be based on clinical or immunological parameters, and viral variants with 
more complex resistance will be selected. [237] Also, an increasing proportion of individuals 
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initiating first-line ART in LMIC are not naïve, but rather re-initiating a NNRTI-based first-
line treatment, and the treatment history may not be known to the health care facility. [249] 
Up to 24% of patients on first-line treatment in SSA experience viral failure within 12 
months. Resistance patterns are homogenous with standard first-line treatment; NNRTI-
mutations and certain NRTI-mutations such as M184V (to FTC) and K65R (to TDF) are 
found. [250, 251] In the absence of pre-treatment resistance testing TDR results in worse 
treatment outcomes. [252] Availability of PI-based second line regimens is often limited in 
LMIC due to the cost being around three times that of the first line regimen, and less than 5% 
of individuals on ART in LMIC are on second-line regimens. [253] 
The current WHO recommendations to defer switch to second line ART if VL is detectable 
but less than 1000 copies/ml, and to repeat VL testing in 2-3 months if VL is ≥1000 
copies/ml before initiation of regimen switch have been questioned, as they may lead to 
development of advanced resistance and increased rates of TDR. A comparative study of 
switch strategies in a high-endemic, low resource setting in SSA is underway. [254, 255] 
As a response to rising NNRTI resistance in LMIC, WHO now recommends the INSTI DTG 
as the preferred core agent in first- and second line ART. [256] Although DTG has a high 
genetic barrier to resistance, treatment success relies on effective companion drugs to avoid 
monotherapy that would inevitably lead to development of resistance. In this context, timely 
switch strategies are of importance. 
1.4.7 Resistance surveillance and epidemiology 
The local prevalence and nature of TDR is of importance to guide recommendations on 
first-line regimens, PrEP and PEP and is ideally studied by surveillance of resistance 
mutations in treatment-naïve individuals close to time of infection. To allow for 
comparisons between geographic areas and over time, a consensus list of Surveillance Drug 
Resistance Mutations (SDRMs) has been developed. The mutations on the list are 
unambiguously related to drug resistance, non-polymorphic, confer drug resistance in all 
common subtypes, and are not too rare in treated patients. [257] The list is integrated in the 
Stanford Calibrated Population Resistance online tool, facilitating analysis of  large 
numbers of sequences. [258] Findings of SDRMs do not always confer clinically relevant 
resistance and require further analysis with one of the clinical algorithms (described in 
1.4.5) as well as interpretation in the context of current ART regimens. [259] 
In high-income countries, prevalence studies are often conducted on a national level and 
often relies on case-based results from individuals routinely tested for drug resistance at 
diagnosis. There is also a European initiative (SPREAD) to merge data and analyse on a 
European level since 2001 [260] and ECDC are currently investigating the possibilities of 
hosting a European HIV TDR surveillance network. [259, 261] 
WHO has designed recommendations on TDR surveillance for LMIC, based on sampling 
of a limited number of individuals representing a certain population. As an increasing 
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proportion of individuals starting first-line ART are already ART-experienced and the 
information on earlier treatment is often insufficient, the updated recommendation focuses 
on PDR in populations initiating ART, independent of duration of infection or earlier 
treatment experience. [154, 253] 
After introduction of ART the prevalence of TDR rose to 10-15% in Europe and USA 
before fully suppressive ART became available. Lately, levels in Europe have stabilized or 
decreased and the last figure is 8.3% 2008 - 2010, but with an increase of NNRTI resistance 
in recently infected patients. [260] In USA the TDR prevalence is 12 - 24% and in Eastern 
Europe and South/Southeast Asia 5-10%. [154]  
A meta-regression-analysis of TDR surveillance studies in LMIC 2001 - 2011 showed a 
significant increase in prevalence of TDR, primarily NNRTI TDR, over time in SSA, 
starting from very low levels before ART rollout. [262] An update until 2016 included all 
PDR and confirmed the trend, with a predicted prevalence of NNRTI PDR for 2016 of 
10.1% in eastern Africa, 11% in southern Africa and 7.2% in western and central Africa. A 
high NNRTI PDR prevalence of 9.4% was also estimated for Latin America and the 
Caribbean. NRTI PDR was stable in most areas, slowly increasing in southern and eastern 
Africa, but remaining <5% in all regions. PI resistance was very rare and detected in less 
than one percent of cases. Individuals with a reported history of ART exposure were prone 
to have a combination of NRTI and NNRTI resistance and were three times as likely to 
experience viral failure as naïve patients. [249] 
WHO reports that six out of eleven LMICs surveyed for PDR worldwide 2014-2016, had 
NNRTI resistance at or above 10%, the critical threshold for interventions set by WHO; 
Argentina, Guatemala, Namibia, Nicaragua, Uganda and Zimbabwe. [263] This highlights 
that not only SSA but also the Americas need updated strategies on HIVDR. 
The TDR prevalence in Sweden has been lower than in other parts of Europe. The overall 
prevalence was 5.6% in a study on data from 2003 - 2010. [264] In our study 2010 - 2016 
we estimated an overall prevalence of 7.1% with a rise in NNRTI-resistance. TDR to 
NNRTI in migrants from SSA rose significantly from 0% in 2010 to 16% in 2016, 
mirroring the increase of NNRTI-resistance in SSA. [265] 
A meta-analysis of more than 50,000 ART-naïve individuals from both LMIC and upper-
income settings showed concordance in findings of mutations that conferred clinical 
resistance. M184V was the most common transmitted major NRTI-mutation and found in 
54% of individuals with NRTI resistance in LMIC and 31% in high-income countries. 
M184I, K65R, L74V/I, Y115F and the TAMs K70R and T215Y/F were also common 
transmitted mutations. K103N, Y181C and G190A were the most common NNRTI-
mutations in all regions and subtypes. V106M was associated to subtype C and the fourth 
most common NNRTI-mutation in that subtype. [246] 
Generally, there is a need for standardization of methodologies for drug resistance 
surveillance, including continuous updates of the SDRM list and compartmentalized 
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analyses of specific populations. ART-naïve, undiagnosed individuals with TDR HIV are 
important in forwarding resistance mutations, but knowledge on the tendency of different 
drug resistance mutations to be maintained in transmission clusters is insufficient, 
especially in LMIC. [217] 
1.4.8 WHO global action plan on HIV drug resistance 
The rising prevalence of NNRTI resistance, especially in southern and eastern Africa but also 
in Latin America, threatens to undermine the efforts to achieve the 90-90-90 targets by 2020 
and to end the AIDS epidemic by 2030. Mathematical modelling predicts that if no action is 
taken, HIVDR can result in 890,000 deaths in AIDS and 450,000 new HIV-1 infections in 
SSA during 2016-2030. [266] WHO has responded by a broad approach to prevent and 
manage HIVDR, as formulated in the WHO global action plan on HIV drug resistance 2017-
2021. The objectives include strengthening laboratory capacity for access to VL and HIVDR 
testing as well as epidemiological surveillance and modelling to increase knowledge on 
HIVDR.  [253] 
 
Fig 12.  The five main objectives of the WHO Global Action Plan on HIV drug resistance 
2017-2021. Reprinted with permission. [253] 
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2 AIMS 
The overall aim of my thesis was to study molecular and epidemiological aspects of the 
Swedish HIV-1 epidemic in relation to the HIV-1 pandemic, using the Swedish InfCareHIV 
cohort. Emphasis was on pre-treatment drug resistance, undiagnosed HIV-1 infections and 
estimates of time to diagnosis. 
The specific aims were: 
Paper I 
• To evaluate mixed basecalls in pol sequences as a measure of viral diversity and a 
method to distinguish between recent and long-term HIV-1 infection.  
• To apply the method in surveys of transmitted HIV-1 drug resistance from low- and 
middle income countries. 
Paper II 
• To study transmitted drug resistance in treatment naïve individuals newly diagnosed 
with HIV-1 in Sweden 2010-2016. 
Paper III 
• To evaluate two modelling methods for estimation of  the proportion of undiagnosed 
persons living with HIV-1 in Sweden, using national surveillance data and data from 
the Swedish InfCare HIV-1 cohort. 
Paper IV 
• To evaluate an in-house method for high-throughput sequencing of the HIV-1 pol 
gene with respect to clinical utility including subtype inclusivity. 
• To study pre-treatment drug resistance mutations in major and minority viral variants 
in patients diagnosed with HIV-1 in Sweden during 2017-2019. 
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3 MATERIALS AND METHODS 
3.1 SOURCES OF DATA 
3.1.1 The national register of HIV and AIDS 
Case reporting of HIV/AIDS is mandatory in Sweden since 1983 and reporting of AIDS was 
mandatory until 2005. National data are collected under code at the Public Health Agency of 
Sweden, and this register was used in Paper III. 
3.1.2 InfCareHIV Sweden 
InfCareHIV is a national decision tool, clinical database and research database initiated in 
2003 by Prof Sönnerborg and with full national coverage since 2009. [71] All individuals 
under HIV care in Sweden are entered into the database. Historical data since the 1980’s have 
been entered retrospectively for some clinics, e.g. in Stockholm. The database contains 
clinical data on diagnosis, treatment initiation and regimens, epidemiological data on origin 
and ethnicity of the patients, transmission mode, age, sex etc. Laboratory results such as 
CD4+ T-cell counts, HIV-1 RNA viral loads and resistance tests are continuously entered. 
Sanger sequences from resistance testing of PR/RT and integrase are stored in the database. 
Research on the database is permitted by the steering committee after ethical approval. 
InfCareHIV laid the foundation for this thesis and is the main data source for Papers I-IV. 
For these studies several downloads from the database were done to MsAccess. The 
downloads were done with pseudonymized patient identifiers (A five-digit code). The dates 
for the downloads are given in the respective papers. 
3.2 LABORATORY METHODS 
3.2.1 Viral load monitoring 
HIV-1 viral loads are reported to InfCareHIV from several clinical laboratories that have 
been using different assays over the years. At Karolinska University laboratory, the NASBA® 
(Organon Teknika) assay was used from 1994 until 1997 when the Roche Amplicor® HIV-1 
monitor test was introduced, and since then sequential versions of Cobas Amplicor® and 
Cobas TaqMan® (Roche Molecular Systems, Basel, Switzerland) have been used. The current 
assay is the Cobas®HIV-1 assay (Roche Molecular Systems, Basel, Switzerland). 
3.2.2 CD4+ T-cell counts 
CD4+ T-cell counts in InfCareHIV have been determined with routine flow cytometry. The 
values are for most clinics automatically transferred from the laboratory to the database. 
3.2.3 HIV drug resistance testing 
Population-based Sanger sequences of the pol gene including PR/RT were produced at 
Clinical Microbiology at Karolinska University Hospital, Stockholm, Sahlgrenska University 
  43 
Hospital, Gothenburg or the Swedish Institute for Infectious Disease Control, Stockholm, 
respectively, per established in house protocols (1993-1999) or commercial methods (2000–
2002: Trugene® HIV-1 Genotyping kit, Canada; 2003-2019: ViroSeq® HIV-1 genotyping kit, 
Abbott Molecular, US). Population-based IN sequences were produced with ViroSeq® HIV 
Integrase genotyping kit, Abbott Molecular, US. Sequences for Paper I were generated 1993 
– 2010, sequences in Paper II were produced 2010-2017 and sequences for Paper IV 2017-
2019.  
In Paper I HIV-1 protease and reverse transcriptase sequences from 36 surveys of TDR 
conducted according to WHO guidelines in Africa, Asia and Latin America during 2005–
2009 were included. The sequencing and base-calling of pure and mixed nucleotide positions  
was performed at WHO-designated laboratories from plasma or serum specimens according 
to local routine. 
For detection of Surveillance Drug Resistance Mutations in Paper II the Stanford Calibrated 
Population Resistance Tool (https://hivdb.stanford.edu/cpr/) applying the WHO 2009 SDRM 
list was used. For clinical interpretations of resistance in Papers II and IV, Stanford HIVdb 
(https://hivdb.stanford.edu/hivdb/) was used. The current available version of the tools at the 
time for each study was used, for details please refer to the individual papers. For analysis of 
DRM in the HTS in-house pipeline in paper IV, a modified version of the list from Stanford 
HIVdb 8.7 was used, excluding polymorphisms in the protease of limited significance. 
3.2.4 HIV-1 subtyping and phylogenetic analysis 
In Paper I the REGA HIV-1 Subtyping Tool v2 was applied to assign subtypes. [267, 268] 
In Paper II subtypes were determined by a maximum-likelihood phylogeny including the 
Los Alamos Sequence Database Subtype Reference Alignment [269], reconstructed in 
PhyML [270] with aLRT-SH branch support [271, 272]. Additional maximum-likelihood 
phylogenies were constructed for subtype/recombinant groups and cluster analysis was 
performed using Cluster Picker. [273] After exploratory analyses a cut-off for branch support 
of 0.90 and a distance threshold of 6% were chosen. [274] 
In Paper IV The subtyping was performed using REGA version 3 and COMET. The unique 
recombinant forms (URFs) from HTS were confirmed using SimPlot analysis followed by 
fragment specific phylogenetic analysis as described by us. [27] 
3.2.5 Sequence polymorphism analysis 
In Paper I, the percentage of mixed base calls representing more than one base in a certain 
position (R, Y, K, M, S, W, B, D, H, V or N) in each sequence was calculated using BioEdit 
(http://www.mbio.ncsu.edu/BioEdit/bioedit.html) and Microsoft Excel. 
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3.2.6 High throughput sequencing 
In Paper IV, a 3,000 bp fragment of pol including PR, RT and IN was amplified and 
sequenced on Illumina® HiSeq2500 producing paired end sequences of read length 250 bp. 
QIAamp Viral RNA extraction kit (Qiagen, Germany) was used for extraction of viral RNA. 
SuperScript™ III One-Step RT-PCR System with Platinum™ Taq DNA Polymerase (Life 
Technology,US ) was used for cDNA synthesis and first round PCR with primers 1810F and 
5220R. The following nested PCR applied KAPA HiFi HotStart ReadyMix PCR kit and 
primers 2002F and 5087R. The sequences of the primers are displayed in table 1. Purification 
of the amplified products was performed with QIAamp gel extraction kit (Qiagen, Germany). 
HTS was performed as described by our group. [275] In short, purified amplicons were 
fragmented and library preparation was performed using NEBNext® Ultra™ DNA Library 
Prep Kit for Illumina® (New England Biolab, USA) with multiplexed NEB next adaptors. 
During analysis, samples were pooled together with unrelated, non-viral, libraries.   
Table 1. Primer information 
Primer Sequence Name HXB2 Position 
5’-GCTACACTAGAAGAAATGATGACAGCATG-3’ 1810F 1810 → 1838 
5’-CCCTAGTGGGATGTGTACTTCTGA-3’ 5220R 5197 → 5220 
5’-TGCAGGGCCCCTAGGAAAAAGGGCTGTT-3’ 2002F 2002 → 2029 
5’- ATCCTGTCTACYTGCCACACAAYC-3 5087R 5064 → 5087 
3.2.7 Bioinformatics pipeline 
In Paper IV, an in-house bioinformatics pipeline was used to process FASTQ Illumina 
output files. The adaptor was removed by TrimGalore version 0.6.2, and Sickle version 1.33 
was used to filter low-quality bases with phred value score <Q30. FastUniq was used to 
remove duplicate reads. The Iterative Virus Assembler (IVA) was used for de novo assembly. 
Bowtie2 was then used to re-align the processed reads against the individual pol gene 
sequence, to create a consensus sequence covering the protease, reverse transcriptase and 
integrase gene (HXB2 co-ordinate: 2253- 5050). For quantification of the mutations, the 
selected reads were then aligned against Pol protein sequences using the blastx program from 
BLAST package. Best blastx hit was chosen for each read for the amino acid counting which 
was performed with an in-house script. The method provides reliable identification of viral 
variants down to 1% of the total viral population. [276] 
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3.3 MATHEMATICAL MODELS 
3.3.1 CD4+ T-cell decline trajectory model 
In Paper II and IV, a CD4+ T-cell decline trajectory [74] was applied to estimate whether 
individuals were infected with HIV-1 before or after migration to Sweden. The method is 
based on the intercept and the slope of CD4+ T-cell decline in seroconverters with 
consideration of differences depending on age and ethnicity. Individuals with primary HIV 
infection (PHI) or ART exposure were excluded from analysis. With input of the CD4+ T-cell 
count at diagnosis, age and region of origin (Europe, Africa or other) the year of infection 
was estimated and compared to migration data. 
3.3.2 SSOPHIE 
A European cohort initiative, Stochastic Simulation of Outcomes of People with HIV In 
Europe project in EuroCoord (SSOPHIE) was formed to find improved models and resulted 
in development of an individual-based stochastic simulation model of the HIV-1 epidemic, 
based on models of HIV-progression and the effect of ART. [92] We applied this model to 
the Swedish HIV-1 epidemic in Paper III. The model is informed by multiple variables; 
biomarkers, treatment coverage and effects, the HIV-care continuum and risk of death from 
both HIV-related and non-related causes. The effects of ART and HIV pathogenesis are held 
fixed. Individuals of HIV-positive populations are modelled from the start of the epidemic 
onward. The model is run multiple times in a Bayesian framework and output is calibrated to 
surveillance data. It is designed for good coverage of data but can be run on limited data, 
which results in larger plausibility bounds. An advantage of the model is that risk groups can 
be modelled separately, and that the model attempts to account for migration from high-
incidence countries in sub-Saharan Africa. Uncertainty in the model is displayed by a 90% 
plausibility range (PR) of estimates. [93]  
3.3.3 ECDC HIV modelling tool 
In Paper III, the incidence method of the ECDC HIV Modelling Tool version 1.3.0 was 
applied to Swedish data. The tool was developed by ECDC for modelling of European HIV-1 
epidemics and is available online. (https://ecdc.europa.eu/en/publications-data/hiv-modelling-
tool) It is a multi-state back-calculation model based on maximum likelihood statistics. [94, 
95] The input required is the annual number of HIV diagnoses, AIDS diagnoses and 
concurrent HIV and AIDS diagnoses. It is recommended to also enter annual number of HIV 
diagnoses stratified by CD4+ T-cell count, and optional, deaths in HIV-positive. The method 
first estimates HIV incidence over time and time to diagnosis by CD4 count strata, and then 
estimates the size of the HIV-positive population. Migration is not addressed in the model, 
but subgroups can be analyzed separately. 
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3.4 STATISTICAL ANALYSIS 
In Paper I, unpaired t-test was used to compare the proportion of mixed bases in recent 
versus chronic HIV-1 infection. The t-test was compromised by non-normal distribution of 
data and hence the significance was confirmed with bootstrap analysis. The non-parametric 
Mann-Whitney test was used for sub-analyses of smaller groups. GraphPad online application 
respectively GraphPad software were used (GraphPad Software, San Diego, USA). 
In Paper II Chi-square test was applied to investigate relationships between categorical 
outcomes and categorical variables. Bivariate logistic regression was used to explore 
associations between epidemiological and viral variables with the categorical outcome TDR. 
Ordered logistic regression was used to assess trends over the study period. A confidence 
level of 95% was chosen, with p-values less than 0.05 indicating statistical significance. Data 
were analyzed with StataSE 12 software (Stata Corp. College Station, USA). 
In Paper IV Based on prior knowledge of clinical relevance and similarity to Sanger DRM 
testing a level of ≥20% of DRM in the viral population was chosen as primary outcome for 
statistical analysis of PDR. Chi-square test and unpaired t-test were applied as adequate to 
investigate statistical associations. When Chi-square test was compromised by too few 
observations, it was replaced by Fisher´s exact test. Bivariate logistic regression was used to 
explore associations between epidemiological and viral variables and two categorical 
outcomes, successful HTS and DRM in PR/RT in ≥20% of the viral population, respectively. 
Variables with a p-value <0.2 were included in multivariable logistic regression models, built 
using the “stepwise” procedure. A p-value <0.05 was considered significant in the final 
models. Crude and adjusted odds ratios (ORs) with 95% confidence intervals were presented.  
3.5 ETHICAL CONSIDERATIONS 
All four studies were conducted in accordance with the Declaration of Helsinki and approved 
by the Regional ethics committee in Stockholm (Diary numbers 2005/1167-31/3, 2007/1533-
32, 2014/928-31, and 2017/1421-31) and by the Regional ethics committee in Gothenburg 
(Diary number 532-11 including amendments 20111118, 20140422, 20170516 and 
20181015).  
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4 RESULTS AND DISCUSSION 
4.1 PAPER I  
“Evaluation of sequence ambiguities of the HIV-1 pol gene as a method to identify 
recent HIV-1 infection in transmitted drug resistance surveys” 
Study background 
To distinguish recent from long-standing HIV-1 infections is of relevance for the estimation 
of HIV-1 incidence, and in the study of TDR since resistance mutations may revert with time 
from infection. Several commonly used serological assays for identification of recent HIV-1 
infection, such as the BED assay, are limited by relatively high false recent results and 
suboptimal performance in non-B subtypes. At the time of the study, the WHO 
recommendation on study of TDR in LMIC was a truncated consecutive sampling for 
resistace testing of ≤47 specimens from recently infected individuals within a geographic 
region. To ensure recent infection, epidemiological surrogate criteria were used, but there was 
an imminent need to ascertain their validity by an accessible biomarker. Due to the subtype 
diversity of the Swedish HIV-1 epidemic and research collaborations with Ethiopia and 
Vietnam, we had access to a suitable reference material from individuals with recent (≤1 
year) and chronic (>1 year) infections. 
Results and discussion 
We corroborated that there was a significant difference (p<0.0001, unpaired t-test) in the 
proportion of mixed (ambiguous) base calls in routine pol sequences between recently ((≤1 
year, n=250) and chronically (>1 year, n=441) infected individuals. This was already shown in 
subtype B by the Swiss Zurich Primary HIV Infection Study [113] and the Canadian HIV 
Strain and Drug Resistance Surveillance Program. [112]  
 
Fig 13. Proportion of mixed bases (ambiguities) in pol sequences from recently and 
chronically infected individuals. Reprinted with permission. [110] 
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Our main contribution was that we demonstrated that the finding was consistent over all 
tested non-B subtypes (A1, C and CRF01_AE), strengthening the validity of the approach in 
LMICs where non-B subtypes dominate. From our reference material we calculated an 
optimized cutoff of 0.47 % mixed bases that identified recent HIV infection with a sensitivity 
of 89% and a specificity of 75%. 
Our analysis suggested that 71% of the individuals in TDR surveys, selected to have recent 
infection, were sampled within a year from infection. Interestingly, the proportion varied 
from 22% to 100% between surveys, suggesting that the specificity of selection criteria 
varied drastically between settings. Technical differences between labs may also have 
impacted on these regional differences. 
That our reference dataset consisted of sequences from different labs and different times was 
a possible source of error, but also a strength since it showed the universality of the method 
under real-life circumstances. We chose the best possible cutoff to discriminate between 
recent and chronic infection in our dataset and reached a sensitivity of 89% and a specificity 
of 75%. This makes the method useful in an epidemiological context, especially in 
combination with other biomarkers, but not specific enough to use on the individual level.  
The sensitivity is hampered by infections with more than one viral variant, if the infecting 
variants differ significantly, and a probable reason for low specificity is decreased diversity in 
advanced disease. Both specificity and sensitivity are negatively affected by low sequence 
quality and possible operator errors of over- respectively under-calling mixed bases. Since 
seroconversion data on chronic infections in non-B subtypes was scarce, we used CD4+ T-
cell counts as a surrogate variable to define this group. To ascertain that the sequences chosen 
were from chronically infected individuals, we chose a low CD4+ count of ≤200 cells/mm3, 
and this means that individuals with a long duration are probable to be overrepresented and 
we might have overestimated the difference in mixed bases between the groups.  
Testing the method on a training dataset of seroconverters different from the reference dataset 
would have been a way to strengthen the validity. It can be argued that the dichotomized 
classification between recent and chronic infection is artificial and since it is proven that viral 
diversity increases linearly, the proportion of ambiguous base calls could also be used on a 
linear scale. Next generation sequencing provides opportunities to make more advanced 
analyses of viral diversity [114, 116] but given that population-based sequencing is still the 
standard method worldwide, analysis of mixed base calls is cost-effective and accessible. 
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4.2 PAPERS II AND IV 
“Increase in transmitted drug resistance in migrants from sub-Saharan Africa 
diagnosed with HIV-1 in Sweden” 
“High-throughput sequencing for in-depth analysis of pre-treatment HIV-1 drug 
resistance in Sweden.” 
Study background 
TDR prevalence has been low in Sweden compared to other parts of the Western world, and 
associated to MSM and subtype B. With increasing impact of migration on the Swedish HIV-
1 epidemic and reports on increasing NNRTI-resistance in SSA, we hypothesized that 
individuals with origin in SSA, but diagnosed with HIV-1 in Sweden would be increasingly 
prone to harbor NNRTI resistant virus. The nationwide coverage of the InfCareHIV database 
made it possible to conduct a retrospective study on naïve individuals 2010-2016 in Paper II. 
The findings from Paper II and the global introduction of INSTI as a cornerstone of ART, 
motivated us to study resistance in both major and minority viral variants including INSTI 
mutations, in a well-characterized subset of newly diagnosed individuals in Sweden 2017-
2019 in Paper IV. We embraced the WHO concept of pre-treatment drug resistance since an 
increasing proportion of individuals entering HIV-1 care in Sweden have an ART-history and 
we included both naïve and treatment experienced individuals. By applying HTS to a relevant 
cohort, we also aimed to evaluate our in-house HTS method and bioinformatics pipeline for 
clinical use. 
Results and discussion 
In Paper II, we showed an increase in the overall prevalence of SDRMs in naïve individuals 
compared to earlier data, although confidence intervals overlap. The TDR prevalence 2010-
2016 was 7.1% (95% CI 5.8–8.3%) compared to 5.6% (95% CI 4.5–6.9%) in a study from 
2003-2010. [264] There was a significant increase in NNRTI TDR during the study period 
from 1.5% (95% CI 0–2.9%) in 2010 to 6.2% (95% CI 2.9–9.5%) in 2016 (P=0.006, ordered 
logistic regression).  
NNRTI resistance was associated with reported infection is SSA, origin in SSA and infection 
with subtype C. The prevalence of NNRTI TDR in individuals infected in SSA increased 
from no cases in 2010 to 16% (95% CI 5.0–27%) in 2016 (P=0.002, ordered logistic 
regression). The most common NNRTI mutation was K103N, a mutation that confers high-
level resistance to EFV. Of 46 individuals from SSA with TDR, only three were reported 
and/or estimated with the CD4+ T-cell trajectory model to have been infected after arrival to 
Sweden. Phylogenetic analysis did not support spread of resistant strains in Sweden within 
this group. Base-line resistance testing is already implemented in the Swedish HIV-1 clinics, 
but the limitation of population-based sequencing in detecting potentially relevant NNRTI-
resistant minority variants calls for caution in using EFV in individuals with epidemiological 
links to SSA. 
 50 
 
Fig 14. Prevalence of transmitted drug resistance per drug class in patients infected in sub-
Saharan Africa. N=absolute number of patients with any TDR per year. TDR, transmitted 
drug resistance. [265] Reprinted with permission. 
In contrast, NRTI resistance did not increase over the study period and was associated to 
infection in Sweden and subtype B. The most common singleton NRTI-mutation was M41L 
and a large cluster in MSM (n=26) of subtype B HIV-1 with M41L dating back to 1994 was 
described. M41L is a TAM and a remnant from resistance development during older ART-
regimens containing thymidine analogues not in use today (i.e. AZT). M41L does not 
compromise modern ART, but the propagation of M41L from naïve individuals is an 
important proof-of-concept of the ability of fitness-neutral DRM to persist and spread 
clonally over decades.    
In Paper IV, the first objective was to evaluate our pol HTS assay in a proper context of 
individuals presenting with viremic HIV-1 infection in Sweden. Our results with 87% success 
in producing interpretable sequences from study samples (195/224) were reassuring for 
subtype inclusivity. However, the method had lower success in samples with low viral loads 
than the currently used Sanger sequencing of PR/RT. Individuals with low viral loads were 
commonly on non-suppressive treatment and at high risk of HIVDR. To be able to use HTS 
for both clinical resistance testing and studies of resistance development in low level viremia, 
we need to improve the amplification step of the protocol in samples with low viral loads. It 
is not surprising that it is harder to amplify larger fragments (3,000bp in the HTS assay 
compared to 1,800bp for PR/RT and 900bp for integrase in the Sanger assay). One way to 
obtain HTS sequences could be to use the efficient amplification step from our Sanger 
protocol and then apply HTS to the amplicons. Another could be to increase input volume to 
increase the number of targets for PCR in the amplification step.    
The second objective of Paper IV was to study PDR with HTS. For clarity we separated the 
analyses for PR/RT DRM and INSTI DRM. We found DRMs in PR/RT in 49% of the study 
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subjects, with all findings displayed according to proportion of the total viral population 
(<5%, 5-19% or ≥20%) in figure 15 a,b and c. Findings of DRM <5% were predicted by 
lower viral load (adjusted OR 0.61 95% CI(0.43-0.86); p=0.005) and origin in Eastern 
Europe or Central Asia (adjusted OR 3.72 95% CI(1.21-11.46); p=0.022). DRM 5-19% was 
not statistically associated to any parameter. We chose DRM ≥20% as cutoff for our analysis 
of PDR in relation to epidemiological and clinical data based on evidence of consensus with 
Sanger sequencing at this level. DRM in PR/RT in ≥20% of the viral population was found in 
18% (n=36) of the study subjects. In bivariate analysis it was associated with female sex 
(crude OR 0.35 for men 95% CI(0.16-0.76); p=0.008), previous HIV-1 diagnosis abroad 
(crude OR 3.44 95% CI(1.41-8.40); p=0.007), previous ART exposure (crude OR 11.22 95% 
CI(3.80-33.07); p<0.0001) and to being born in Asia (crude OR 4.14 95% CI (1.13-15); 
p=0.032). Origin in SSA was bordering a statistically significant association (OR 2.48 (95% 
CI 0.96-6.45) p=0.06, bivariate logistic regression) In a multivariable logistic regression 
model DRM ≥20% was significantly predicted by ART exposure (adjusted OR 8.70 95% 
CI(2.54-29.77); p=0.001) and origin in Asia (adjusted OR 15.23 95% CI(2.13-108.67); 
p=0.007). Female sex and origin in SSA were associated to ART exposure and were therefore 
not needed for prediction and dropped from the model during the “stepwise” procedure. 
Individuals from Asia with PDR did not report ART exposure, suggesting that the findings in 
them might be due to transmitted rather than acquired resistance. PDR was in most cases due 
to NNRTI resistance DRMs, and the mutations and combinations of mutations found in 
individuals from SSA had higher predicted impact on drug effects than those found in 
individuals from Asia. 
We wanted to study INSTI resistance and polymorphisms in a situation when few individuals 
are expected to have been exposed to INSTI at diagnosis in Sweden, a situation that is 
probable to change in the next few years due to massive roll-out of DTG in LMIC to tackle 
the emergence of NNRTI-resistance. We did not find any evidence of transmitted or acquired 
INSTI resistance, but in 8% of individuals we found major INSTI mutations in low 
proportions of the virus population. Of special interest is when the finding in four individuals 
was combined with the polymorphism L74M/I that has been suggested to contribute to failure 
on cabotegravir regimens in a recent study. [185] All findings in the integrase gene are 
displayed in figure 15 d. 
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Fig 15. All findings of DRM with HTS in Paper IV according to their proportion of the total 
viral population. a) PI DRMs b) NRTI DRMs c) NNRTI DRMs d) INSTI DRMs 
The roll-out of PrEP (TDF+FTC) in high risk MSM in Sweden is an important preventive 
intervention that was introduced during 2018. Vigilance of TDR in this group is vital, since 
introduction or development of resistant strains could lead to fast clonal spread of TDR HIV-
1. So far there are no clinical reports of PrEP failure due to TDR in Sweden. In Paper II we 
found two MSM with strains that were highly resistant to both agents in the current PrEP 
regimen. In all patients, eight individuals had viruses with decreased sensitivity to TDF, eight 
to FTC/3TC and nine to both. In Paper IV one ART naïve MSM who had acquired HIV-1 in 
Latin America had a virus with decreased sensitivity to FTC/3TC. Two ART experienced 
females from SSA had FTC/3TC resistance and one heterosexual man from SSA had 
combined resistance to both PrEP antivirals.  
Migrant MSM are of increasing importance to the Swedish HIV-1 epidemic, and in our 
cohort in Paper IV, half (53%) of MSM newly diagnosed with HIV-1 were of non-Swedish 
origin. Introduction of resistant strains from settings with emerging resistance such as SSA or 
Latin America as well as the increased risk of exposure to resistant HIV-1 during travel 
strengthen the indication of HIVDR monitoring to ensure future PrEP efficacy.  
The results from Paper IV cannot be directly compared to the results from Paper II. Paper 
II aimed to study TDR (although the register-based approach is probable to have resulted in 
inclusion of some ART experienced individuals) over several years and to draw conclusions 
on general prevalence and trends of TDR in newly diagnosed individuals in Sweden. Paper 
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IV is not a true TDR prevalence study and instead aimed to study PDR in a more well-
described, restricted cohort and to evaluate a new sequencing approach. However, both 
studies clearly show that the global emergence of NNRTI resistance impacts on the Swedish 
HIV-1 epidemic, and that is one of the major findings in this thesis.   
4.3 PAPER III 
“Challenges in modelling the proportion of undiagnosed HIV infections in Sweden.” 
Study background 
Sweden has already reached and exceeded the second and third “90ies” of the 90-90-90 
target. However, the true proportion of undiagnosed individuals i.e. the first target with 90% 
of individuals with HIV infection aware of their HIV status, remains elusive. The high 
proportion of migrants in newly diagnosed individuals in Sweden needs to be accounted for 
in estimating the number of undiagnosed individuals, since migrants arriving with HIV 
infection are only part of the Swedish undiagnosed population after arrival. We set out to 
estimate the undiagnosed proportion of PLHIV in Sweden with two mathematical models 
designed for European conditions.  
Results and discussion 
With the SSOPHIE model, the estimated proportion of undiagnosed PLHIV in 2013 was 26% 
(n=2,100; 90% PR 900-5,000) and with the ECDC HIV Modelling Tool the proportion was 
21% (n=2,013; 95% CI 1,831-2,189) in 2013 and 20% (n=2,107; 95% CI 1,688-2,577) in 
2016. The models are based on different statistical methods (Bayesian vs. maximum 
likelihood) and this explains the difference in the wide plausibility range of the SSOPHIE 
estimate compared to the narrow confidence interval surrounding the ECDC Modelling Tool 
point estimate, even though much of the input data were the same. There is no real 
disagreement between the methods but the estimates differ in statistical precision as measured 
by PR and CI, respectively. 
Both models support definition of subpopulations of individuals that share epidemiological 
characteristics. This is an advantage in the Swedish situation with a compartmentalized 
epidemic. However, it is always a simplification since communication between transmission 
groups and misclassification do occur. In our work we decided to model MSM, heterosexual 
migrants from SSA and all other heterosexual transmission separately. PWID and migrants 
from South East Asia were too few to be modelled separately even though they are important 
groups in Sweden. Characteristics of individuals with heterosexual transmission that were not 
migrants from SSA were diverse. This group included both migrants from areas other than 
SSA and Swedish born, making this grouping questionable for modelling.  
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Fig 16.  Number of undiagnosed PLHIV in Sweden 1980-2013 as estimated by SSOPHIE. 
[99] Reprinted with permission. 
 
 
 
Fig 17. Number of diagnosed and undiagnosed PLHIV in Sweden 1980-2016 as estimated by 
ECDC HIV modelling Tool. [99] Reprinted with permission. 
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The results of the subpopulation modelling agreed on that the proportion of undiagnosed 
individuals was lowest in the MSM group; 17% (n=600; 90% PR 100-2,000) and 15% 
(n=369; 95% CI 299-434), in the SSOPHIE and ECDC models respectively. This is in line 
with our prior knowledge that MSM in Sweden with HIV-1 are less likely to present late to 
care than other groups of patients. [79]  
The population with the highest proportion of undiagnosed infections was migrants from 
SSA. The SSOPHIE model produced gender specific estimates of 35% (n=300; 90% PR 200-
700) in male and 34% (n=400; 90% PR (200-800) in female migrants from SSA. The ECDC 
modelling Tool estimated that 21% (n=530; 95% CI 436-632) of migrants from SSA with 
HIV-infection were undiagnosed. In this group where we anticipated an important impact of 
infections acquired before arrival to Sweden, the influence of migration was modelled in 
SSOPHIE with support of Spectrum/EPP estimates from SSA and data on migration from 
SSA to Sweden. This approach has several weaknesses, one being the difficulty to obtain 
comprehensive migration data on time of arrival to Sweden for migrants. We used data from 
Statistics Sweden on the number of permits to stay in Sweden issued per year to individuals 
from SSA as a proxy for time of arrival. However, for asylum seekers there may be a long 
delay from arrival to Sweden until acquisition of a permit to stay, and the delay has varied 
over the years. Not all migrants are granted a permit to stay after the application process and 
those who are declined will not be accounted for in our data. Neither did we use any data on 
emigration from Sweden. 
The assumptions regarding migration are vital to produce correct estimates on the size of the 
undiagnosed group. As is increasingly emphasized, the HIV epidemics in countries with 
generalized epidemics are also diverse and prevalence may differ greatly between 
geographical areas and populations within one country, meaning that using general 
prevalence in the country of origin for migrants may be misleading. 
To our disappointment, we did not obtain an estimate of the undiagnosed proportion of HIV 
in Sweden that was reliable enough to use for public health purposes. The uncertainty bounds 
of the SSOPHIE estimate were wide, and the ECDC-model did not take migration into 
account. Compared to our preconceptions the estimated proportions of undiagnosed PLHIV 
from the models were unexpectedly high. 
The way forward towards more reliable estimates lies in development of both new models 
and appropriate collection of surveillance data to meet the challenges of producing estimates 
in a country with small numbers of PLHIV and massive impact of migration from all over the 
world. 
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5 CONCLUSIONS 
▪ Viral diversity measured by the proportion of mixed bases in routinely generated  
population-based pol sequences discriminates reasonably well between recent and 
chronic HIV-1 infection in the major subtypes. Further improvements might include: 
➢ Combinations with other biomarkers that could strengthen the estimates. 
➢ Standardization of sequencing to minimize technical error. 
➢ Viral diversity assessed with NGS/HTS is a promising development of the 
approach. 
 
▪ Transmitted drug resistance to NNRTI in migrants from sub-Saharan Africa increased 
substantially between 2010 – 2016. 
➢ The global trend in NNRTI resistance is reflected in migrants in Sweden. 
➢ Sweden has potential to be a beacon for future resistance trends.  
 
▪ Pre-treatment drug resistance can be analysed in a wide range of HIV-1 subtypes with 
our in-house NGS/HTS assay. 
➢ Pre-treatment drug resistance in PR/RT in our cohort was predicted by ART 
exposure and origin in Asia. 
➢ NNRTI resistance is the most clinically important finding and occurs in 
individuals from all over the world. 
➢ No evidence of transmitted or acquired resistance to INSTI were found, and 
few individuals were exposed to INSTI. 
 
▪ Cases of HIV-1 with resistance to one or both components of PrEP are found in 
newly diagnosed MSM in Sweden. 
➢ Migration and travel are important in shaping the Swedish HIV-1 epidemic in 
MSM. 
➢ Vigilance of TDR affecting PrEP efficacy in the MSM group is important. 
 
▪ The proportion of undiagnosed people living with HIV in Sweden is still uncertain. 
➢ Mathematical models suitable for low-prevalence settings with high impact of 
migration need further development.  
➢ High quality case-based data on migration in HIV-positive migrants as well as 
population-based data on general migration from high-endemic countries is 
needed for reliable estimates. 
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6 FUTURE PERSPECTIVES 
During the work with this thesis important changes in HIV-1 epidemiology and drug 
resistance epidemiology and a rapid technical development have taken place both in Sweden 
and globally and these trends are of importance for future research, treatment and prevention 
of HIV-1 in Sweden.  
Migration and travel are central components of the HIV-1 pandemic and Sweden has the 
highest proportion of migrants among newly diagnosed PLHIV in Europe. An increasing 
proportion of migrants initiating HIV care in Sweden are already diagnosed and many are on 
ART, but information about this is insufficient. The classical epidemiological 
compartmentalization in Swedish MSM vs heterosexual migrants from high-endemic settings 
is challenged by an increasing proportion of migrant MSM in the population with new HIV-1 
diagnoses in Sweden. In both migrants and Swedish born with new HIV-1 diagnoses it is 
often uncertain if the HIV-1 infection was contracted in Sweden or abroad. Better methods to 
determine when an individual was infected in relation to migration and travel is still a high 
priority. This important question is addressed by our group as a main objective in the ongoing 
prospective TIME-study, where time to diagnosis in newly diagnosed PLHIV is estimated 
with a combination of NGS viral diversity, serological markers and CD4+ T-cell counts in a 
Bayesian framework. We hope that this will create a robust method that can be integrated in 
epidemiological studies of HIV-1 as well as in surveillance activities in Sweden. In addition, 
more detailed collection of surveillance data of HIV-1 in Sweden to identify previously 
diagnosed infections and individuals already under effective would increase possibilities to 
estimate undiagnosed infections and to design effective interventions for early diagnosis and 
prevention. 
NGS/HTS is rapidly moving from an exclusive research technology into an everyday clinical 
tool. We intend to use the experiences from Paper IV to introduce NGS/HTS resistance 
testing of HIV-1 in the clinic within the next few years. However, our results with limited 
success in samples with low viral loads show that improvements are needed to fulfill clinical 
requirements. Routine collection of NGS/HTS data would facilitate surveillance of PDR and 
make it possible to detect a possible increase in PDR to integrase inhibitors or other important 
drugs before it has large clinical consequences. Collection of more data will help to further 
elucidate the clinical significance of low level DRMs and the adequate level of reporting. It is 
probable that the clinical importance of a certain percentage of resistant variants in a position 
is related not only to the tested drug, but to potency of companion drugs, viral load, 
adherence, and potentially other host factors and viral subtype. Machine learning approaches 
is an interesting approach to find patterns in big data sets and could potentially be used to 
investigate this.    
PrEP is so far a success story in preventing HIV-1 transmission in MSM and has been well-
received when recently introduced in Sweden. It has the potential to prevent many of the 
transmissions among MSM residing in Sweden, both in-country transmissions and during 
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travel. To ensure that the PrEP regimens are effective, up-to-date surveillance of TDR is a 
necessity and this could be accomplished by the methods we have used in this thesis. 
Baseline resistance testing is a cornerstone of HIVDR management in a high-income setting, 
but an increasing proportion of HIV positive individuals presenting for care in Sweden are 
already diagnosed and on suppressive ART. This is good news but means that baseline 
resistance testing and complete treatment history is often not available. In an era of treatment 
simplification, proviral resistance testing is an interesting concept, but not without caveats, 
and needs to be further investigated for clinical use. 
Time is closing in on the global achievements of the 90-90-90 target goals. It is highly 
unlikely that they will be reached universally by next year. Sweden is in a good position with 
excellent treatment rates and viral suppression rates. However, many individuals are still 
being diagnosed late in Sweden and the number and characteristics of undiagnosed people 
living with HIV is unclear. Joint efforts in epidemiology, diagnostic and educational activities 
are needed to enumerate and diminish undiagnosed infections. The global progress towards 
95-95-95 in 2030 depends on the success in tackling HIVDR and on elimination of stigma 
and political obstacles that prevent access to high-quality HIV services for all PLHIV. 
The diverse population of PLHIV in Sweden, combined with a strong national surveillance 
program and a national database collecting real-time clinical data, provides opportunities for 
future research of global interest although the number of PLHIV in Sweden is relatively 
small. 
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